Amino acid composition and uses thereof
Amino acid compositions enhance intestinal stem cell proliferation and differentiation to address gastrointestinal toxicity from radiation and chemotherapy, restoring the intestinal barrier and alleviating symptoms.
Patent Information
- Application Number
- JP2023060554
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-11-14
- Filing Date
- 2023-04-04
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2037-10-04
AI Technical Summary
Current treatments for radiation- and chemotherapy-induced gastrointestinal toxicity are inadequate, primarily focusing on symptomatic relief without effectively addressing the underlying damage to intestinal epithelial cells, leading to malabsorption, inflammation, and disruption of the intestinal barrier.
Amino acid compositions, such as those containing threonine, valine, tyrosine, tryptophan, and serine, are administered to promote cell survival, proliferation, and differentiation of stem and progenitor cells, enhancing the repair and regeneration of the gastrointestinal mucosa.
The amino acid compositions improve the proliferation and function of intestinal stem cells, restoring the intestinal barrier function, reducing symptoms like diarrhea and nausea, and enhancing overall gastrointestinal health post-radiation or chemotherapy.
Smart Images

Figure 0007593577000001 
Figure 0007593577000002 
Figure 0007593577000003
Abstract
Description
[Technical field]
[0001] <Related Applications> This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 403,965, filed October 4, 2016, and U.S. Provisional Application No. 62 / 421,443, filed November 14, 2016, each of which is incorporated herein by reference. [Background technology]
[0002] <Background of the invention> Human intestinal epithelial cells are generated from a fixed population of stem cells that functionally reside in the lower part of the intestinal crypts, which in mice contain rapidly dividing crypt basal columnar cells (CBCs) and inactive "+4" cells above Paneth cells. 14-16 These stem cells give rise to absorptive enterocytes, mucus cells, Paneth cells and enteroendocrine cells. 17 Differentiation of each cell type occurs as cells migrate upward into the villi (absorptive, mucus and endocrine cells) or concentrate downward at the bottom of the crypts (Paneth cells). The multiple mechanisms responsible for these complex events are not fully understood.
[0003] Radiation and / or chemotherapy can cause significant damage to the lining of the gastrointestinal (GI) tract, with moderate to high doses resulting in the destruction of cells with clonogenic potential essential for the continuous replacement of cells shed from the upper part of the villi during normal proliferation, maturation, and differentiation processes.
[0004] The toxic effects of radiation exposure and / or chemotherapy on the gastrointestinal system can cause symptoms such as nausea, vomiting, diarrhea, electrolyte imbalance, and dehydration, adversely affecting the health of patients during the course of cancer treatment. Radiation exposure adversely affects intestinal epithelial cells, which undergo rapid mitosis in the submucosal crypts. In therapeutic radiation exposure, gastrointestinal toxicity is often the dose-limiting factor for treatment and can adversely affect the quality of life of patients. To minimize toxicity, therapeutic compounds and supportive care may be used, but these methods are not completely effective.
[0005] There is growing interest in developing formulations that reduce short-term and long-term gastrointestinal toxicity in cancer patients and victims of radiation disasters. 5,15,34,37 There are only two FDA-approved drugs currently used to treat radiation syndrome: Neupogen® and Pegfilgrastim (granulocyte-colony stimulating factor). Both increase the survival rate of patients exposed to radiation doses that suppress bone marrow function. However, there are no drugs that specifically address gastrointestinal toxicity. Treatment of gastrointestinal toxicity is primarily symptomatic, with antidiarrheals to prevent fluid loss, smectites to absorb bile salts, opioids to reduce stomach and rectal pain, steroids to reduce inflammation, and, in extreme cases, parenteral medications to correct malabsorption of nutrients and electrolytes. Other agents that can be used to reduce gastrointestinal toxicity include: 1) Statins and / or angiotensin-converting enzymes: These agents have been used in definitive pelvic radiotherapy and have proven effective due to their anti-inflammatory, anti-fibrotic and anti-thrombotic effects. 2) Antioxidants such as Vitamin E and / or Selenium. 3) Teduglutide, a glucagon-like peptide-2 analogue, which must be administered before radiation. 4) Sucralfate, a highly sulfated polyanionic disaccharide that is useful in epithelial healing but has not been shown to be useful in radiation-induced GI toxicity. 5) Nitroxides such as hydroxylamines (Tempol), which act through their antioxidant properties. 6) Dithiolthione (oltipraz), which acts by increasing intracellular sulfhydryls. 7) Isoflavone (genistein): A tyrosine kinase inhibitor and antioxidant. 8) Cox inhibitors (celecoxib, aspirin), which act by increasing Cox2 activity and prostaglandin synthesis. 8) Probiotics, preparations containing large amounts of viable microorganisms that may modify the host microflora and potentially have an effect on radiation-induced GI toxicity. 5 . [Stacey, R. & Green, JT Radiation-induced small bowel disease: latest developments and clinical guidance. Ther. Adv. Chronic Disease, 5, 15-29, doi:10.1177 / 2040622313510730 (2014).]
[0006] Migration of crypts to villi takes 5-7 days. Therefore, gastrointestinal toxicity appears in the first week after radiation exposure and / or chemotherapy and is the most important dose-limiting factor in cancer treatment. Even at low doses, progressive loss of the villi and brush border of the small intestine is observed within a few days after irradiation and / or chemotherapy. Crypt cells can rapidly regrow the area after irradiation and therapy at low to moderate doses of irradiation and / or chemotherapy, but disappear at a logarithmic rate after high doses of irradiation and / or chemotherapy.
[0007] Radiation and / or chemotherapy are particularly destructive to the villous epithelium, where the absorption of nutrients and electrolytes occurs. In the villous epithelium, cell loss and renewal occurs continuously, providing a constant supply of immature enterocytes derived from precursor cells located in the lower pole of the crypts of Lieberkühn, which leave the proliferative compartment at the base of the crypt and migrate to the apex of the carpet. During their short life span, these enterocytes gradually mature into villous cells along the crypt-villus axis. Even moderate doses of radiation and / or chemotherapy can deplete almost the entire villous epithelium, destroying not only existing villous cells, but also the stem and / or progenitor cells from which new villous cells are formed.
[0008] Mature differentiated trophoblastic cells are responsible for sodium, chloride, and subsequent fluid absorption, whereas the less differentiated immature epithelial cells located in the crypts are primarily responsible for chloride (Cl - The absence of absorptive villous epithelial cells results in a malabsorption state in which unabsorbed nutrients, electrolytes, and water are released into the distal gastrointestinal tract, causing nausea, vomiting, and diarrhea.
[0009] Stem cell-mediated repopulation of trophoblast cells, through in situ cell proliferation and / or potential migration into tissues by circulating progenitor cells from distant sites, may contribute to tissue-level recovery from the effects of intense irradiation and / or chemotherapy. 11-13 Therefore, loss of crypt stem cells or villus endothelial cells is thought to be responsible for radiation- and / or chemotherapy-induced intestinal damage.
[0010] Damage to the GI tract not only results in malabsorption and loss of nutrients, minerals, and fluids, but also disrupts the intestinal barrier function. Leakage from the GI tract allows food-borne pathogens and other antigenic substances to easily cross the mucosal barrier and enter the systemic compartment, causing inflammation, bacteremia, and endotoxemia. GI toxicity usually occurs only at fairly high doses, but doses as low as 5-12 Gy (conventional radiotherapy fractionation uses 1.8-2 Gy per fraction) can cause, for example, acute radiation enteritis, diarrhea, and abdominal pain within days after irradiation. Chronic radiation enteritis can develop between 18 months and 6 years after radiation therapy, but can occur even after 15 years. 27-29 .
[0011] Treatment options for radiation and / or chemotherapy-induced enteritis are limited: conventional treatments include antidiarrheal medications to prevent fluid loss, smectites as adsorbents for bile salts, opioids to relieve gastric or rectal pain, and steroids to reduce inflammation.
[0012] A common treatment for radiation and / or chemotherapy-induced enteritis is bowel rest using total parenteral nutrition (TPN). However, it remains unclear whether parenteral nutrition meets the nutritional needs of patients or whether it actually has a therapeutic effect on radiation and / or chemotherapy-induced enteritis. Although TPN may correct nutritional imbalances in certain patients, severe radiation and / or chemotherapy-induced enteritis may develop. 37 TPN also induces intestinal atrophy, usually within 48 hours of administration. TPN also weakens the mechanical and immunological barriers. 38 .
[0013] The formulation used in U.S. Pat. No. 8,993,522 acts to modify rehydration through amino acid-bound sodium transport, reduce anion secretion from the crypts by selecting a set of amino acids with antisecretory properties, and strengthen the mucosa using amino acids shown to strengthen the mucosal barrier.
[0014] There is a need for improved compositions for treating radiation and / or chemotherapy induced GI damage secondary to loss of proliferating stem and / or progenitor cells, and compositions for treating and improving diseases or conditions associated with mucosal barrier function (e.g. wound healing), treating skin conditions (e.g. atopic dermatitis, psoriasis, pressure sores, or conditions associated with skin aging), treating pulmonary diseases (e.g. asthma), improving mucosal barrier function, and / or treating gastrointestinal mucosal damage in subjects in need thereof. Summary of the Invention
[0015] <Summary of the Invention> The compositions described herein are amino acid compositions for treating gastrointestinal, pulmonary, and skin diseases. In one aspect, the disclosure provides compositions and methods for promoting cell survival, cell proliferation, cell migration, cell maturation, and / or cell differentiation. In certain embodiments, the disclosure provides compositions and methods for promoting the survival, proliferation, and / or development of stem cells and / or progenitor cells. Cell growth can include, for example, migration, maturation, and / or differentiation. The disclosure also provides compositions and methods for treating and improving diseases or conditions associated with mucosal barrier function (e.g., wound healing), treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or conditions associated with skin aging), treating pulmonary diseases (e.g., asthma), improving mucosal barrier function, and / or treating damage to the gastrointestinal mucosa in a subject in need thereof.
[0016] This cell proliferation and / or growth can be used to improve the proliferation and function of stem and progenitor cells present in various organ systems and locations within the body. The stem and / or progenitor cells can be, for example, in the small intestine or derived from other tissues, including, but not limited to, skin, bone marrow, lung, neurons, pancreas, muscle, skeletal tissue, vascular endothelial cells, and corneal epithelial cells. The stem and / or progenitor cells can be adult stem cells, embryonic stem cells, or cancer stem cells. In one embodiment, a composition useful for treating a condition described herein comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine, and optionally an acceptable carrier.
[0017] In certain embodiments, the composition of the present disclosure does not include one or more amino acids selected from the group consisting of lysine, glycine, isoleucine, and asparagine. In certain embodiments, the composition does not include lysine, glycine, aspartic acid, isoleucine, and asparagine. In another particular embodiment, the composition does not include or includes negligible amounts of serine, lysine, glycine, asparagine, isoleucine, and asparagine. In certain embodiments, the composition does not include glutamine and / or methionine, and any di-, oligo-, or polypeptide or protein that can be hydrolyzed to glutamine and / or methionine. In certain embodiments, the composition does not include methionine.
[0018] Alternatively, in certain embodiments, even if these amino acids are present in the composition, they are not present in an amount that inhibits the survival, proliferation, and / or growth of stem cells and / or progenitor cells. In some embodiments, the composition does not include serine. In some embodiments, the composition does not include cysteine. In certain embodiments, even if these amino acids are present in the composition, they are not present in an amount that adversely affects the treatment of a disease or condition associated with mucosal barrier function (e.g., wound healing), the treatment of a skin condition (e.g., atopic dermatitis, psoriasis, bed sores, or a condition associated with skin aging), the treatment of a lung disease (e.g., asthma), the improvement of mucosal barrier function, and / or the treatment of damage to the GI mucosa.
[0019] When these amino acids are present in the composition, the acceptable concentrations are, for example, about 0.4 to about 1.5, about 0.7 to about 1.3, or about 0.9 to about 1.1 grams / liter for threonine, about 0.7 to about 1.7, about 0.9 to about 1.5, or about 1.1 to about 1.3 grams / liter for valine, about 0.6 to about 1.6, about 0.8 to about 1.4, or about 1.0 to about 1.2 grams / liter for serine, about 0.05 to about 0.4, or about 0.1 to about 0.3 grams / liter for tyrosine, and about 1.1 to about 2.1, about 1.3 to about 1.9, or about 1.5 to about 1.7 grams / liter for tryptophan. In certain embodiments, the concentration is the number of grams of amino acid per liter of solution. In certain embodiments, the solution contains water. In certain embodiments, the therapeutic composition comprises threonine (about 1.0 grams / liter), valine (about 1.2 grams / liter), serine (about 1.1 grams / liter), tyrosine (about 0.2 grams / liter), and tryptophan (about 1.6 grams / liter). In one embodiment, the composition does not comprise serine. In some embodiments, the composition does not comprise methionine. In some embodiments, the composition does not comprise cysteine.
[0020] In some embodiments, the total osmolality of the compositions is from about 100 mosm to about 280 mosm, or from about 150 mosm to about 280 mosm.
[0021] The pH of the composition may be, for example, about 2.5 to about 8.5. In certain embodiments, the pH of the composition is about 2.5 to about 6.5, about 3.0 to about 6.0, about 3.5 to about 5.5, about 3.9 to about 5.0, or about 4.2 to about 4.6. In other embodiments, the pH of the composition is about 6.5 to about 8.5, about 7.0 to about 8.0, or about 7.2 to about 7.8.
[0022] In certain embodiments, the composition is administered as part of a solution or drink, powder, pill, gel, cream, ointment, matrix, or on a bandage, hi certain embodiments, the composition is administered as part of a matrix delivery system.
[0023] The composition can be administered systemically or locally. In certain embodiments, the composition is used ex vivo or in vitro to promote cell survival, proliferation, and / or growth. In certain embodiments, the composition is used to treat a disease or condition associated with mucosal barrier function (e.g., wound healing), to treat a skin condition (e.g., atopic dermatitis, psoriasis, bed sores, or a condition associated with skin aging), to treat a lung disease (e.g., asthma), to improve mucosal barrier function, and / or to treat damage to the GI mucosa.
[0024] In certain embodiments, the compositions also include additives (eg, nutrients, electrolytes, vitamins, minerals, etc.).
[0025] Without wishing to be bound by any particular theory, the compositions and methods are believed to prevent DNA damage and are useful for preventing DNA damage and / or repairing damaged DNA. In another embodiment, the compositions and methods promote the survival, proliferation, and growth of stem cells by preventing DNA damage and / or repairing damaged DNA.
[0026] In another aspect, the present disclosure provides a method of treating a pulmonary disease in a subject in need thereof. In another aspect, the present disclosure provides a method of treating a pulmonary disease in a subject in need thereof, the method comprising the steps of: improving lung healing, reducing symptoms of pneumonia, airway resistance, (airway resistance) The present invention provides compositions and methods for improving or alleviating lung disease and / or improving lung function in a subject in need thereof. In certain embodiments, the pulmonary condition is lung injury, pneumonia, or asthma. In certain embodiments, the pulmonary condition is associated with increased airway resistance. In certain embodiments, the pulmonary condition is associated with impaired barrier function. In certain embodiments, the compositions are administered systemically or by inhalation. In certain embodiments, the compositions and methods are useful for improving lung healing, alleviating pneumonia, reducing airway resistance, and improving lung function, for example, after radiation exposure and / or chemotherapy.
[0027] In another embodiment, the present disclosure provides compositions and methods for treating bone marrow suppression caused, for example, by drugs, viruses, bacteria, toxins, chemicals, or vitamin deficiencies. For example, in certain embodiments, the compositions and methods are used to treat patients with low platelet counts (thrombocytopenia), for example, caused by dengue virus infection.
[0028] In another aspect, the disclosure provides a method for treating a GI or GI tract disease (e.g., radiation injury, ischemic colitis, infection, trauma), or any other condition associated with mucosal barrier function and / or integrity. In certain embodiments, a method for treating a disease or condition associated with mucosal barrier function is provided. In certain embodiments, the disease or condition associated with mucosal barrier function is a malfunction of the mucosal barrier. In certain embodiments, the treatment of a disease or condition associated with mucosal barrier function is wound healing, healing, treatment in a subject in need of treatment for damage to the GI mucosa. In certain embodiments, a treatment is provided for a subject in need of treatment for damage to the GI mucosa. In certain embodiments, the GI mucosa is a small intestinal mucosa. In certain embodiments, the composition is used for treatment after surgery (e.g., intestinal surgery). In certain embodiments, the composition is used for treatment of any disease or condition that leads to ischemic bowel, including, for example, hypotension, shock, thrombosis, ileus, etc.
[0029] One composition useful for treating radiation enteritis is the amino acid-based oral rehydration solution (AA-ORS) described in U.S. Patent No. 8,993,522, which is incorporated herein by reference. AA-ORS is a composition for improving small intestinal health, the composition is formulated for enteral administration and contains the free amino acids threonine, valine, tryptophan, serine and tyrosine, and water. The composition does not contain the free amino acid glutamine or glutamine-containing dipeptides, but if the free amino acid glutamine and / or glutamine-containing dipeptides are present, the total concentration of the free amino acid glutamine and glutamine-containing dipeptides is less than 50 mg / l. The composition does not contain glucose, but if glucose is present, the concentration of glucose is less than 1 g / l. The composition does not contain the free amino acid methionine or methionine-containing peptides, and optionally does not contain lysine, glycine, aspartic acid, and / or isoleucine, and optionally does not contain electrolytes, vitamins, minerals, and / or flavoring agents.
[0030] In another aspect, the present disclosure provides a method of treating a skin condition (e.g., atopic dermatitis, psoriasis, bed sores, or a condition associated with skin aging) in a subject in need of such treatment, the method comprising administering to the subject a composition described herein. In certain embodiments, the skin condition is atopic dermatitis, psoriasis, skin aging associated with skin aging, or a bed sore. In certain embodiments, the compositions and methods described herein are useful, for example, in cosmetic applications where rejuvenation of various layers of the skin and / or tissues underlying the skin is desired.
[0031] <Definition> The terms "improving a skin condition" or "treating a skin condition" include prophylactically preventing or therapeutically treating a skin condition, the effects of which include at least one of the following: prevention of skin thickening, loss of skin elasticity, and reduction of fine lines and wrinkles.
[0032] As used herein, the terms "epidermis" or "epidermal" refer to the outermost layer of the skin.
[0033] As used herein, the term "topical application" means applying or spreading the compositions of the present invention onto the surface of the epidermal tissue.
[0034] As used herein, the term "dermatologically acceptable" means that the composition or components thereof so described are suitable for use in contact with mammalian epidermal tissue and are free from undue toxicity, incompatibility, instability, allergic response, and the like.
[0035] The term "therapeutically effective amount" as used herein refers to an amount of a compound or composition sufficient to provide a favorable effect, preferably favorable skin appearance and / or feeling. A therapeutically effective amount according to the present disclosure is an amount of amino acid that alone or in combination with other agents regulates and / or improves the skin.
[0036] As used herein, "amelioration" or any grammatical variant thereof (e.g., ameliorate, ameliorating, amelioration, etc.) includes, but is not limited to, delaying the onset of or reducing the severity of a disease or condition. As used herein, "amelioration" does not require complete elimination of symptoms.
[0037] As used herein, the term "effective amount" or "significant amount" refers to an amount that is capable of treating or ameliorating a disease or condition, or that is capable of producing the intended therapeutic effect.
[0038] The term "health functional food" refers to food that is prepared or processed into tablets, capsules, powders, granules, liquids, pills, or any other form using raw materials or ingredients that have functions beneficial to the human body.
[0039] The term "functional" refers to beneficial effects on human health, including, for example, structural or functional regulation of nutrients, immune system, inflammation, and the like. (inflammation) , fluid balance, and physiological functions.
[0040] The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a compound is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin.
[0041] As used herein, "treatment" or any grammatical variations thereof (e.g., treat, treating, treatment, etc.) includes, but is not limited to, alleviating the symptoms of a disease or condition and / or reducing, inhibiting, preventing, ameliorating, or affecting the progression, severity and / or extent of a disease or condition.
[0042] As used herein, the term "consisting essentially of" limits the scope of components and steps to the particular materials or steps, and only those components and steps that do not substantially adversely affect the compositions and methods for promoting stem cell growth that are a basic and novel feature of the present invention. [Brief description of the drawings]
[0043] Figure 1A and Figure 1B show that AA-ORS increased crypt number and villus length after radiation. Physiological saline (saline) was used as a control. Saline and AA-ORS were administered by gastric gavage. There were six mice per radiation group (0, 1, 3, 5, 6, 7, 9, 13, and 15 Gy) with and without treatment. [Figure 1A] Figure 1A shows the semi-log survival curves showing the effect of AA-ORS on crypt number. AA-ORS shifted the graph to the left. Crypt survival curves were modeled using a one-hit multi-target cell survival model to evaluate the biological effect. The survival probability of mitotic cells in the crypts after radiation was calculated using the formula [S=1-(1-e^-D / D0)n]. S represents the percentage of mitotic cells in the crypts that survived at each radiation dose, and D represents the radiation dose. D0 is a measure of the inherent radiation resistance of the crypt genitalia. The Dq values of saline-treated and AA-ORS-treated mice are represented by black and gray arrows, respectively. Dq is calculated from the formula Dq=D0In n. Without limiting certain cell sensitivity, N values were 10.4±0.2 and 5.3±0.1 (P<0.001), showing almost double the precursor units per circumference of the control. When a constant D0 (4.8±0.1 Gy) was constrained, the difference remained significant at 8.8±0.4 to 6.1±0.3 (P<0.001). [Figure 1B]FIG. 1B shows the villus height after treatment with saline and AA-ORS in irradiated mice. Mice treated with AA-ORS had a significant increase in villus height compared to mice receiving saline. The number of crypts per circumference was counted and villus length was measured from 10 sections taken from the ileum. Data are shown as mean±SEM for 6 mice per group. * indicates a statistically significant difference (P<0.01). Saline (saline) was used as a control, and both saline and AA-ORS were administered by gavage.
[0044] [Figure 2A] Figure 2A shows confocal micrographs along the length of the villi for longitudinal ileal sections with prominently stained epithelial cells. Paraffin-embedded tissue of 5 μm thickness was used. Cell nuclei were stained with DAPI (dark grey) and Edu-positive epithelial cells were stained light grey. The migration distance by Edu-positive cells was measured along the height of the villus using Image Pro Plus software. Bars represent 50 μm. At least five well-oriented villi were counted per tissue section and the results were averaged. Edu-positive cells were observed up to the tip of the villi in 5 Gy-irradiated tissue but not in mice treated with AA-ORS.
[0045] [Figure 2B] Figure 2B shows migration distance of EdU positive cells at 72 hours. Saline-treated mice irradiated with 5 Gy had a significant decrease in cell migration distance (black bars) compared to 0 Gy. Mice treated with AA-ORS had an increase in migration distance compared to non-irradiated and irradiated saline-treated mice. Values are means ± SEM of six mice per group.
[0046] [Figure 3A]Figure 3A shows Ussing chamber flux studies with 22Na and 36Cl, demonstrating the effect of AA-ORS on sodium and chloride absorption. AA-ORS increased net sodium (JnetNa) and net chloride (JnetCl) absorption in 0 Gy and 5 Gy irradiated tissues (n=8). [Figure 3B] Figure 3B shows Ussing chamber flux studies with 22Na and 36Cl, demonstrating the effect of AA-ORS on sodium and chloride absorption. AA-ORS increased net sodium (JnetNa) and net chloride (JnetCl) absorption in 0 Gy and 5 Gy irradiated tissues (n=8).
[0047] [Figure 3C] Figure 3C is an immunohistochemistry diagram showing a magnified view of NHE3 expression (light grey) along the brush border membrane (BBM) of villous epithelial cells (white arrows). Paraffin-embedded tissue of 5 μm thickness was used. Cell nuclei were stained with DAPI (dark grey). At least five well-oriented villi were used.
[0048] [Figure 3D] FIG. 3D shows Western blot analysis for NHE3 protein.
[0049] [Figure 3E] Figure 3E shows a graph of NHE3 protein density in intestinal tissues of mice treated with saline (black bars) or AA-ORS (hatched bars) after 0 or 5 Gy irradiation. Immunoblots were repeated four times. Values are means ± SEM of n = 4. * indicates statistically significant difference (P < 0.05) from saline-treated animals.
[0050] [Figure 3F]Figure 3F shows NHE3 transcript levels in intestinal tissues of mice treated with saline (black bars) or AA-ORS (hatched bars) after 0 or 5 Gy irradiation. Values are means ± SEM of n = 6. * indicates statistically significant difference from saline-treated animals (P < 0.05). Saline or AA-ORS was administered for 6 days.
[0051] 4A-4D show glucose-stimulated sodium absorption and SGLT1 protein levels. [Figure 4A] Figure 4A shows the effect of AA-ORS on glucose-bound sodium absorption in an Ussing chamber flux study using 22Na. AA-ORS treatment increased JnetNa absorption in 5 Gy-irradiated tissues (n=8). [Figure 4B] Figure 4B shows Western blot analysis for SGLT1 protein and β-galactosidase, showing that AA-ORS treatment increased protein levels in trophoblast cells from 0 Gy and 5 Gy mice. Immunoblots were repeated four times. [Figure 4C] Figure 4C shows normalized SGLT1 protein levels from Western analysis. When compared with 5 Gy mice, 5 Gy-irradiated mice treated with AA-ORS showed significant differences in SGLT1 protein levels. [Figure 4D] Figure 4D shows SGLT1 transcript levels in intestinal tissues of mice treated with saline (black bars) or AA-ORS (hatched bars) after 0 or 5 Gy irradiation. Values are means ± SEM of n = 6. * indicates statistically significant difference from saline-treated animals (P < 0.05). Saline or AA-ORS was administered for 6 days.
[0052] Figures 5A to 5G show the protein levels and mRNA expression of Lgr5, BMI1, p-AKT, AKT, pERK, and ERK in trophoblastic epithelial cells of mice treated with saline and AA-ORS after 0 or 5 Gy irradiation. Figure 5H shows Western blot analysis for Lgr5, BMI1, p-AKT, AKT, p-ERK, and ERK. Immunoblots were repeated at least four times, and qPCR was repeated at least six times. [Figure 5A] Figure 5A is a Western blot analysis for stem cell and proliferation markers (Lgr5, BMI1, p-AKT, AKT, p-ERK, ERK, and PCNA). Protein bands of interest were normalized to the total amount of protein in each lane using Coomassie blue staining. [Figure 5B] FIG. 5B is a Western blot analysis for apoptotic proteins (Bc12, Bax, cleaved caspase-3, caspase-3 and p53). [Figure 5C] FIG. 5C shows Lgr5 mRNA levels in mice treated with saline or AA-ORS and irradiated with 0 Gy or 5 Gy. [Figure 5D] FIG. 5D shows the change in BMI1 mRNA levels in mice treated with saline or AA-ORS and irradiated with 0 Gy or 5 Gy. [Figure 5E] FIG. 5E shows the change in ERK mRNA levels in mice treated with saline or AA-ORS and irradiated with 0 Gy or 5 Gy. [Figure 5F] FIG. 5F shows the changes in AKT mRNA levels in mice treated with saline or AA-ORS and irradiated with 0 Gy or 5 Gy. [Figure 5G] Figure 5G shows caspase-3 mRNA expression. Values are mean ± SEM of n=6, 3 repeats in different mice. #P<0.05 and *P<0.001 compared to saline control. [Figure 5H]Figure 5H is a Western blot analysis for Lgr5, BMI1, p-AKT, AKT, pERK, and ERK. Protein bands of interest were normalized to the total amount of protein in each lane using Ponceau S staining.
[0053] 6A to 6G show the expression of Lgr5 in the ileal mucosa after 0 Gy (left) and 5 Gy (right) treatment with saline (top) or AA-ORS (bottom). + , Ki67 + and PCNA + Representative micrographs of cell distribution are shown. [Figure 6A] Figure 6A shows immunostaining of Lgr5, and Lgr5+ cells were found in the lower third of the crypt. Mice irradiated with 5 Gy showed a significant decrease in Lgr5+ stem cells in the ileal crypt, while AA-ORS increased Lgr5+ stem cells. Scale bar represents 25 μm. [Figure 6B] Figure 6B shows the average number of Lgr5+ cells expressed within the crypts. Error bars represent SEM. [Figure 6C] Figure 6C shows immunostaining for Ki-67, a proliferation marker, and the number of Ki-67 expressing cells was not significantly different in 0 Gy irradiated mice treated with AA-ORS compared to the saline-treated group. 5 Gy irradiated mice showed a significant increase in Ki67+ cells treated with AA-ORS. Scale bar represents 100 μm. [Figure 6D] (D) Mean number of Ki-67 expressing cells in crypt and / or villus cells. Error bars represent SEM. [Figure 6E] Figure 6E shows the number and distribution of PCNA+ cells by immunostaining. PCNA+ cells decreased in mice after 5 Gy irradiation, but increased in mice treated with AA-ORS. The scale bar represents 100 μm. [Figure 6F] (F) Mean number of PCNA-expressing cells in crypt and / or villus cells. Error bars represent SEM. [Figure 6G]Figure 6G shows the protein levels and mRNA expression of cleaved caspase 3, total caspase 3, and p53 in mouse trophoblastic epithelial cells treated with saline and AA-ORS after 0 and 5 Gy irradiation. Immunoblots were repeated at least four times, and q-PCR was repeated at least six times. Western blot analysis for cleaved caspase 3, total caspase 3, and p53. Protein bands of interest were normalized to the total amount of protein in each lane using Ponceau S staining.
[0054] [Figure 7] FIG. 7 shows a schematic of small intestinal villi and enterocytes. AA-ORS treatment increases rapidly dividing Lgr5-positive stem cells and proliferation markers p-ERK, p-AKT, and PCNA. The treatment also increases cleaved caspase 3, p53, and Bcl-2. AA-ORS treatment increases villus height and increases the expression of NHE3, SGLT1, and β-galactosidase. NHE3, SGLT1, and β-galactosidase increase electrolyte absorption, sodium-bound glucose absorption, and degradation of disaccharides at the brush border membrane, respectively. The diagram of enterocytes in the upper right corner shows functional improvement in NHE3-mediated Na+ absorption and glucose-bound sodium transport by AA-ORS.
[0055] Figure 8 shows protein density. Protein density is normalized to b-actin. After 0 or 5 Gy irradiation, saline-treated mice are shown as black bars and AA-ORS-treated mice are shown as hatched bars. Values are mean ± SEM of n=4 replicates in three different mice. #P<0.05 compared to saline control. [Figure 8A] FIG. 8A shows Lgr5 protein. [Figure 8B] FIG. 8B is the Bmil protein. [Figure 8C] FIG. 8C shows p-ERK protein. [Figure 8D] FIG. 8D shows p-AKT protein. [Figure 8E] FIG. 8E shows AKT protein. [Figure 8F] FIG. 8F is caspase-3 protein (normalized to b-actin).
[0056] [Figure 9A] FIG. 9A shows the results of Western analysis demonstrating that gavage with valine increased Lgr5 protein levels in 0 Gy-irradiated and 5 Gy-irradiated mice. [Figure 9B] Figure 9B shows a graphical representation of protein levels of Lgr5 protein in mice treated with valine for 6 days. For Figures 9-13, data are from male NIH Swiss mice (8 weeks) treated with individual amino acids: valine (Figure 9), tryptophan (Figure 10), serine (Figure 11), tyrosine (Figure 12), and threonine (Figure 13) after 6 days of gastric savage (300 μl OD). Animals were sacrificed by CO2 euthanasia on day 6 and tissues were collected for Western blot analysis. Lgr5 (100KD) was used as a marker of crypt stem cell proliferation. These experiments were repeated at least four times on four different mice (data shown).
[0057] [Figure 10A] FIG. 10A shows changes in Lgr5 protein levels due to tryptophan treatment for 6 days. [Figure 10B] FIG. 10B shows a graphical representation of Lgr5 protein levels in mice treated with tryptophan for 6 days.
[0058] [Figure 11A] FIG. 11A shows changes in Lgr5 protein levels following serine treatment for 6 days. [Figure 11B] FIG. 11B shows a graphical representation of Lgr5 protein levels in mice treated with serine for 6 days.
[0059] [Figure 12A] FIG. 12A shows changes in Lgr5 protein levels following 6-day tyrosine treatment. [Figure 12B] FIG. 12B shows a graphical representation of Lgr5 protein levels in mice treated with tyrosine for 6 days.
[0060] [Figure 13] FIG. 13 shows changes in Lgr5 protein levels due to threonine treatment for 6 days.
[0061] Figures 14-20 show the results of allergic asthma and anti-inflammatory airway function in response to treatment with amino acid formulations in a sheep model. In this study, animals will demonstrate both fast and slow airway responses to inhalation challenge with Ascaris suum antigen. Venous blood samples (approximately 3 ml) for pharmacokinetic data can be obtained from the external jugular vein. Airway mechanics measurements are as follows: Unsedated sheep are immobilized in a prone position in a cart with their heads fixed. After topical anesthesia of the nasal passages with 2% lidocaine solution, a balloon catheter is advanced through one nostril into the lower esophagus. The animal is intubated through the other nostril with a cuffed endotracheal tube (the endotracheal tube cuff is inflated only during airway mechanics measurements and during aerosol challenge to prevent undue discomfort; this procedure does not affect airway mechanics). Intrathoracic pressure is estimated with an esophageal balloon catheter (filled with 1 ml of air) positioned 5–10 cm from the gastroesophageal junction. In this position, end-expiratory intrathoracic pressure is -2 to -5 cmH 2The pressure ranges from 0 to 100 psi. Once the balloon is in place, it is secured to remain in place throughout the experiment. The lateral pressure in the trachea is measured using a side-hole catheter (2.5 mm inner diameter) advanced through the tip of the endotracheal tube and positioned distally. Transpulmonary pressure, the difference between intratracheal and intrapleural pressure, is measured with a differential pressure transducer catheter system. For measuring pulmonary resistance (RL), the proximal end of the endotracheal tube is connected to a pneumotachograph. The flow and transpulmonary pressure signals are recorded on an oscilloscope recorder, which is linked to a computer for on-line calculation of RL, derived from transpulmonary pressure, respiratory volume (obtained by digital integration) and flow. Analysis of 5 to 10 breaths is performed in units of L x cm H 2 Used to determine RL in O / L / S.
[0062] <Effects on antigen-induced airway responses> Baseline dose-response curves to aerosolized carbachol are obtained 1-3 days prior to antigen challenge. On the day of dosing, baseline values of pulmonary resistance (RL) are obtained and the sheep are then challenged with Ascaris suum antigen. RL measurements are obtained immediately after challenge, hourly for 1-6 hours post-challenge, and half-hourly for 6-1 / 2-8 hours post-challenge. RL measurements are obtained for 24 hours post-challenge followed by a dose-response curve 24 hours post-challenge. Figures 14-19 show airway responses (PC400), where BSL is baseline and PASC is antigen challenge.
[0063] In the first study, sheep are nebulized with the compound (an amino acid formulation consisting of tyrosine (1.2 mM), threonine (8 mM), valine (10 mM), serine (10 mM) and tryptophan (8 mM), 4 mL of the amino acid formulation administered) using the nebulization system described above 30 minutes or 1 hour before, or 30 minutes or 2 hours after antigen challenge. Measurements of RL are repeated after treatment. Subsequent tests then evaluate the effect of the compound after oral administration. In the oral test, sheep receive an amino acid formulation consisting of tyrosine (1.2 mM), aspartic acid (8 mM), threonine (8 mM), valine (10 mM), serine (10 mM), and 8 oz of the amino acid formulation solution are administered orally, and measurements of RL and airway responsiveness (PC400) are performed as described above.
[0064] [Figure 14] FIG. 14 shows the results of pulmonary resistance (RL) and PC400 (expiratory units) in sheep aerosolized with compound 1 hour prior to antigen challenge compared to controls.
[0065] [Figure 15] FIG. 15 shows the results of pulmonary resistance (RL) and PC400 (expiratory units) in sheep treated with aerosolized compounds 2 hours after antigen challenge compared to controls.
[0066] [Figure 16] FIG. 16 shows the results of pulmonary resistance (RL) and PC400 (expiratory units) in sheep treated with compound by aerosol 30 minutes prior to antigen challenge compared to controls.
[0067] [Figure 17] FIG. 17 shows the results of pulmonary resistance (RL) and PC400 (expiratory units) in sheep treated with aerosolized compounds 30 minutes after antigen challenge compared to controls.
[0068] [Figure 18]FIG. 18 shows pulmonary resistance (RL) and PC400 (expiratory units) results for sheep orally administered compound formulations 30 minutes after antigen challenge compared to controls.
[0069] [Figure 19] FIG. 19 shows pulmonary resistance (RL) and PC400 (expiratory units) results for sheep orally administered compound formulations 2 hours after antigen challenge compared to controls.
[0070] [Figure 20] FIG. 20 shows a summary of asthma study results including mean late airway response (LAR) and airway hyperresponsiveness (AHR) for controls and sheep treated with nebulized compound (5-8 hours) or orally administered amino acid formulations before and after aerosol antigen challenge to examine improvement of airway function anti-inflammatory properties. "*" indicates mean late airway response (5-8 hours). "+" indicates post-challenge / pre-challenge PC400. A ratio close to 1 indicates no airway hyperresponsiveness (AHR).
[0071] [Figure 21] Figure 21 shows the results of the wound healing study. The backs of mice selected for surgery were shaved to remove hair. All surgical procedures were anesthetized with 5% isoflurane in oxygen, and a surgical plane of anesthesia was maintained at 1-3% isoflurane. 3 mm punch biopsies were performed on the backs of 8-week-old NIH Swiss mice. The mouse wound model may be affected by wound contraction due to the presence of a subcutaneous muscle layer (a layer that does not exist in humans). To prevent this wound contraction, a silicone O-ring was used as a splint and held in place by sutures. AA-ORS or saline was used for transparent occlusive dressing of the wound. The dressing was changed daily after measuring the wound area using a caliper. This procedure measures the re-formed epithelium and is similar to wound healing in humans. The results are shown in the figures, and the data are from n=6 mice per group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0072] <Detailed Description> Described herein are amino acid compositions for treating gastrointestinal, pulmonary, and skin diseases. In one aspect, compositions and methods for promoting cell proliferation and / or growth are described. In certain embodiments, the cells are stem and / or progenitor cells. The term "development" as used herein may include, for example, cell migration, maturation, and / or differentiation. The present disclosure also provides compositions and methods for treating wounds, skin conditions (e.g., atopic dermatitis, psoriasis, pressure ulcers, conditions associated with skin aging, cosmetic conditions), lung diseases (e.g., lung injury, pneumonia, or asthma), GI diseases (e.g., radiation injury, ischemic colitis, infection, trauma), or any other condition associated with mucosal barrier function and / or integrity.
[0073] The compositions and methods may be used to enhance stem and / or progenitor cell populations in vivo, ex vivo and / or in vitro. These cells are useful for providing treatments for a number of disease conditions, degenerations and injuries.
[0074] In one embodiment, a method is provided for promoting stem and / or progenitor cell proliferation and / or growth in a subject in need of such treatment by administering a composition of the present disclosure to the subject.
[0075] The subject may be a patient in need of enhanced proliferation and / or growth of stem and / or progenitor cells. The patient may be in need thereof, for example, due to malabsorption, radiation or chemotherapy induced gastrointestinal toxicity, or symptoms associated with infection, cancer or cancer therapy. In one embodiment, the patient is asymptomatic. The subject may be any animal, including, for example, a human. In addition to humans, the animal may be a mammal, such as, for example, a cow, a horse, a sheep, a pig, a goat, a dog, and a cat. The animal may also be, for example, a chicken, a turkey, or a fish.
[0076] In certain embodiments, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, serine, and derivatives thereof. In certain embodiments, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, and aspartic acid. The composition preferably comprises one or more free amino acids selected from the group consisting of threonine, valine, serine, tyrosine, and tryptophan. In certain embodiments, the composition comprises two or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises three or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises four or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises threonine, valine, tyrosine, tryptophan, and aspartic acid. In certain embodiments, the composition comprises the free amino acids threonine, valine, tyrosine, tryptophan, and serine.
[0077] In one embodiment, the therapeutic composition comprises, consists essentially of, or consists of one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, serine, aspartic acid, and derivatives thereof, and optionally includes, for example, pharma- ceutically acceptable carriers, adjuvants, and other active agents. In a particular embodiment, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, serine, and aspartic acid, and optionally includes, for example, pharma- ceutically acceptable carriers, adjuvants, other active agents, and additives (e.g., sugars, electrolytes, vitamins, minerals, etc.).
[0078] In one aspect, the compositions described herein comprise one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, or serine.
[0079] In certain embodiments, the composition does not include one or more amino acids selected from the group consisting of lysine, glycine, isoleucine, and asparagine. In certain embodiments, the composition does not include lysine. In certain embodiments, the composition does not include glycine. In certain embodiments, the composition does not include isoleucine. In certain embodiments, the composition does not include asparagine. In certain embodiments, the composition does not include lysine and glycine. In certain embodiments, the composition does not include lysine and isoleucine. In certain embodiments, the composition does not include lysine and asparagine. In certain embodiments, the composition does not include lysine, glycine, and isoleucine. In certain embodiments, the composition does not include lysine, glycine, and asparag ... isoleucine, and asparagine. In certain embodiments, the composition does not include glycine and isoleucine. In certain embodiments, the composition does not include glycine and asparagine. In certain embodiments, the composition does not include glycine, isoleucine, and asparagine. In certain embodiments, the composition does not include isoleucine and asparagine. In certain embodiments, the composition does not include lysine, glycine, aspartic acid, isoleucine, and asparagine. In another particular embodiment, the composition does not contain, or contains negligible amounts of, serine, lysine, glycine, aspartic acid, isoleucine, and asparagine. In a particular embodiment, the composition does not contain glutamine and / or methionine, and does not contain any di-peptide or protein, oligo-peptide or protein, or polypeptide or protein that can be hydrolyzed to glutamine and / or methionine.
[0080] In certain embodiments, even if these amino acids are present in the composition, they are not present in an amount that inhibits the survival, proliferation, and / or growth of stem cells and / or progenitor cells. In some embodiments, the composition does not contain serine or contains a negligible amount of serine. Here, "negligible" means that the presence of serine does not affect the survival, proliferation, and / or growth of stem cells. Also, "negligible" means that the presence of serine does not have an effect on the disease or condition associated with mucosal barrier function (e.g., wound healing), the treatment of skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or conditions associated with skin aging), the treatment of lung diseases (e.g., asthma), the treatment of mucosal barrier function, and / or the treatment of damage to the gastrointestinal mucosa in a subject in need of such treatment and / or the treatment of such disease and / or condition.
[0081] When these amino acids are present in the composition, the concentrations thereof are, for example, about 0.4 to about 1.5, about 0.7 to about 1.3, or about 0.9 to about 1.1 grams / liter for threonine, about 0.7 to about 1.7, about 0.9 to about 1.5, or about 1.1 to about 1.3 grams / liter for valine, about 0.6 to about 1.6, about 0.8 to about 1.4, or about 1.0 to about 1.2 grams / liter for serine, about 0.05 to about 0.4, or about 0.1 to about 0.3 grams / liter for tyrosine, and about 1.1 to about 2.1, about 1.3 to about 1.9, or about 1.5 to about 1.7 grams / liter for tryptophan. In certain embodiments, the composition comprises threonine (about 1.0 grams / liter), valine (about 1.2 grams / liter), serine (about 1.1 grams / liter), tyrosine (about 0.2 grams / liter), tryptophan (about 1.6 grams / liter), and aspartic acid (about 0.4 to 3.6 grams / liter). In certain embodiments, the composition comprises no serine or a negligible amount of serine. In certain embodiments, the concentration is in grams of amino acid per liter of solution. In certain embodiments, the solution comprises water.
[0082] In one embodiment, the total osmolality of the composition is from about 100 mosm to about 280 mosm, or preferably from about 150 to about 260 mosm.
[0083] The pH of the composition may range from about 2.5 to about 8.5. In certain embodiments, the pH of the composition ranges from about 2.5 to about 6.5, about 3.0 to about 6.0, about 3.5 to about 5.5, about 3.9 to about 5.0, or about 4.2 to about 4.6. In other embodiments, the pH of the composition ranges from about 6.5 to about 8.5, about 7.0 to about 8.0, or about 7.2 to about 7.8.
[0084] In certain embodiments, the pH of the composition is, for example, about 2.5 to about 8.5. In certain embodiments, the pH of the composition is about 2.5 to about 6.5, about 2.5 to about 6.0, about 3.0 to about 6.0, about 3.5 to about 6.0, about 3.9 to about 6.0, about 4.2 to about 6.0, about 3.5 to about 5.5, about 3.9 to about 5.0, or about 4.2 to about 4.6. In other embodiments, the pH is about 6.5 to about 8.5, about 7.0 to about 8.5, about 7.0 to about 8.0, about 7.2 to about 8.0, or about 7.2 to about 7.8.
[0085] In some embodiments, the composition is administered systemically or locally. In certain embodiments, the composition is used ex vivo or in vitro to promote cell survival, proliferation, and / or growth. In certain embodiments, the composition is used to treat a disease or condition associated with mucosal barrier function (e.g., wound healing), to treat a skin condition (e.g., atopic dermatitis, psoriasis, bed sores, or a condition associated with skin aging), to treat a pulmonary disease (e.g., asthma), to improve mucosal barrier function, and / or to treat damage to the GI mucosa. The therapeutic composition can be administered by the enteral route, parenterally, topically, or by inhalation. In certain embodiments, the composition is therapeutic, cosmetic, or nutritional.
[0086] In some embodiments, the compositions described herein (e.g., amino acid-based oral rehydration solution (AA-ORS)) act to correct functional changes that occur in the GI mucosa following radiation exposure. In certain embodiments, the composition is a solution. In certain embodiments, the solution is an amino acid-based oral rehydration solution (AA-ORS). Amino acids can be used to correct the increased paracellular permeability, Cl-, and GI mucosa following radiation exposure. - The AA-ORS is selected to counteract increased secretion and decreased electrolyte absorption. Because the compositions described herein (e.g., AA-ORS) correct functional changes in the GI mucosa, its action is believed to be upstream of current drugs in the pipeline. The compositions can be administered with other therapeutic agents. Recently, it has been found that electrolytes, glucose, and some amino acids are poorly absorbed in the gastrointestinal tract after radiation exposure. Furthermore, glucose and some amino acids are poorly absorbed in the gastrointestinal tract after radiation exposure. + Absorption plus electrogenic Cl - It has been observed that radiation can stimulate secretion and increase paracellular permeability, further complicating radiation-induced diarrhea and increased intestinal permeability. 51,52 Increased paracellular permeability is known to increase the transfer of antigenic material from the intestinal lumen to the systemic compartment, resulting in an increase in inflammatory cytokines. 51 .
[0087] In one embodiment, the compositions of the present disclosure do not contain significant amounts of glucose, glutamine, methionine, and / or lactose. In certain embodiments, the compositions do not contain significant amounts of glucose. In certain embodiments, the compositions do not contain significant amounts of glutamine. In certain embodiments, the compositions do not contain significant amounts of methionine. In certain embodiments, the compositions do not contain methionine. In certain embodiments, the compositions do not contain significant amounts of lactose.
[0088] In one embodiment, the compositions described herein are used as cell culture compositions to promote the survival, growth, and / or proliferation of stem and / or progenitor cells. The cell culture compositions can be used to expand stem and / or progenitor cells to treat various diseases. The compositions can also be administered to stem and / or progenitor cells immediately before and / or after transplantation. The compositions can also be used to increase the proliferation of natural stem cells present in various parts of the body.
[0089] In one embodiment, the disclosure provides a method for improving therapeutic outcomes of transplanted stem and / or progenitor cells, comprising administering a composition in combination with stem and / or progenitor cell transplantation, or as a maintenance or supportive therapy following a transplant, such as bone marrow or liver transplantation. In certain embodiments, provided herein is a maintenance or supportive therapy following, for example, bone marrow or liver transplantation. Administration of the composition can be at or near the site of transplantation of the target stem and / or progenitor cells in a human or non-human animal. In alternative embodiments, further modification of the environment can be performed by providing an influencing factor or by removing undesirable toxic substances from the environment that may adversely affect the administered stem and / or progenitor cells.
[0090] The administered cells may be unmodified or may be engineered to be biased toward a target differentiation endpoint. U.S. Patent Application Publication Nos. 2006 / 0134789 and 2006 / 0110440 provide examples of stem cells engineered for negative and positive differentiation bias, which are incorporated herein by reference in their entireties and are contemplated for use with the methods described herein.
[0091] When the cultured composition or the composition produced in situ is administered to stem and / or progenitor cells, changes occur in the cells' survival and proliferation-related factors and secreted proteins, such as transcription factors. This results in changes in cell activity, particularly promoting cell proliferation, survival and / or growth. Thus, by using the composition of the present invention, the scale of stem and / or progenitor cell production can be increased, and the produced cells can be transplanted to diseased or other sites as a cell therapy to promote cell regeneration and effectively treat various conditions.
[0092] In one embodiment, the compositions described herein can stimulate the survival, proliferation, and / or growth of stem and / or progenitor cells, as evidenced by at least one of the following: 1) increased mRNA and / or protein levels of proliferation markers, such as p-ERK and p-AKT; 2) increased mRNA and / or protein levels of stem cell markers, such as BMI1 and Lgr5; 3) activation of protein kinases, such as MEK and ERK; and 4) a decrease in apoptosis markers, such as cleaved caspase 3.
[0093] ERK is a protein known to transmit cell surface signals to the nucleus to mediate the transcriptional and translational changes necessary to effect proliferation. ERK1 and ERK2 are 44kDa and 42kDa proteins that are important subfamily of protein kinases that regulate a wide range of cellular activities and physiological processes, including cell proliferation and differentiation through downregulation of pro-apoptotic molecules and upregulation of anti-apoptotic molecules. Activation of MEK1 / 2 results in phosphorylation of ERK1 and ERK2. Stimulation of ERK1 / 2 results in phosphorylation of threonine and tyrosine residues, the latter of which dissociates ERK1 / 2 from MEK1 / 2. ERK1 / 2 then translocates to the nucleus. In one embodiment, the compositions described herein are effective to maintain mitogenic stimulation until late G1 phase progresses to S phase.
[0094] AKT is a serine / threonine-specific protein kinase that plays a role in cell proliferation and survival and inhibits apoptosis and metabolism. Phosphorylation of AKT activates AKT. Like pERK, AKT is also known to play a role in cell cycle regulation. AKT also promotes growth factor-mediated cell survival. Various studies have demonstrated the important role of the Akt pathway in preventing apoptotic cell death. 9 PCNA, a unique protein associated with DNA replication and used as a marker of proliferation, was measured following treatment with AA-ORS or saline. PCNA in mice irradiated with 0 and 5 Gy was increased in mice treated with AA-ORS but not in mice treated with saline. Increased PCNA is an early sign of small intestinal epithelial proliferation. Taken together, these studies suggest that treatment with AA-ORS promotes proliferation.
[0095] Caspase-3 is an executioner or effector of apoptosis that cleaves intracellular protein substrates, resulting in apoptosis-associated morphological changes, including DNA degradation and chromatin condensation, as well as membrane blebbing to trigger the apoptotic process. This inactive proenzyme is activated by proteolytic cleavage. 7,46. Study showed that radiation increased caspase-3 and AA-ORS treatment decreased cleaved caspase-3 in trophoblastic epithelial cells from 0Gy and 5Gy mice. Bcl-2, a downstream target of Erk1 / 2, is known to inhibit Bax in the intrinsic proapoptotic pathway. Increased Bcl-2 protein levels by AA-ORS suggests a defense mechanism to prevent apoptosis. However, increased protein levels of Bcl-2 in tissues from irradiated mice may suggest a radioprotective mechanism. A similar increase in Bcl-2 protein levels after irradiation has been reported, consistent with previous findings [Ezekwudo, D.et al. Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett 270, 277-285, doi:10.1016 / j.canlet.2008.05.022 (2008)]. However, Bax protein was not significantly altered by radiation or treatment, suggesting an effect of AA-ORS on apoptosis at a step upstream of Bax26. The increase in p-Akt in mice treated with AA-ORS suggests that the effect may be due to activation of proliferation or inhibition of apoptosis (Figure 5). These results, together with the effects seen on caspase-3 and Bcl-2, could explain the pro-survival effect and increased proliferation observed with AA-ORS treatment. However, further studies will be required to characterize the mechanisms by which AA-ORS activates Erk1 / 2 and Akt, PCNA, caspase-3, Bc1-2, or Bax.
[0096] <p53> Because Akt may also play an important role in malignant transformation, the role of p53, a known tumor suppressor protein, was studied with AA-ORS. Alterations in the p53 protein may suggest that AA-ORS has a tumor suppressor effect. Mutations in the p53 tumor-suppressor 53 gene are the most frequently observed genetic lesions in human cancers. Mice homozygous for the null allele appear normal but are prone to spontaneously developing a variety of tumors. 11 p53 has also been shown to play an important role in radiation response, with the level of p53 accumulation in response to radiation being primarily due to the intensity of DNA damage. 12 Studies have shown that stem cell loss plays an important role in radiation-induced acute intestinal injury and lethality and is regulated by the p53 pathway and its transcriptional targets PUMA and p21. 23,34,37 PUMA-dependent apoptosis rapidly reduces intestinal stem cells (ISCs) and their progenitors within hours of high-dose irradiation. Deficiency of PUMA is crucial against radiation-induced intestinal injury, as it improves animal survival and crypt regeneration by enhancing p21-dependent DNA repair. 24,38 The changes in cleaved caspase-3, together with Lgr5, p-Erk, and p-Akt, suggest that AA-ORS increased villus height in intestinal tissues of irradiated and non-irradiated mice not only through proliferation but also through reduced apoptosis and increased cell survival. To assess whether the increased proliferation and reduced apoptosis resulted in villous epithelial cells being mature, differentiated, and functionally active, Na + Absorptive capacity and glucose-stimulated Na + The amount of Na absorbed in the small intestine was measured. + Both NHE3, the main transporter for absorption, and SGLT1, the transporter for absorbing sodium-bound glucose, were detected only in mature and differentiated trophoblastic cells. They had increased function as well as elevated mRNA and protein levels (Figures 3 and 4). These studies suggest that AA-ORS treatment after radiation increases the absorption of electrolytes and glucose (Figures 3, 4, and 7).
[0097] In one embodiment, the compositions described herein are useful for preventing damage to DNA and / or repairing damaged DNA. In another embodiment, the compositions promote proliferation and / or growth of stem and / or progenitor cells by preventing or reducing damage to DNA and / or repairing damaged DNA.
[0098] <Radiation exposure, crypt counts, villus length, and immunohistochemistry> Increased weight gain and survival were found to be secondary to increased absorptive surface area after increases in crypt number and villus height. Crypt number and villus height were demonstrated to be increased by AA-ORS treatment starting on day 6 after radiation. Crypt survival was examined using a one-hit multitarget cell survival model and it was found that the number of crypt precursor units (N) per ileum circumference was significantly increased (P<0.001) without changes in D0 (4.8±0.1Gy) (Figure 1A). Dq values showed an improvement equivalent to the increased radiation resistance of 1.7Gy with AA-ORS treatment, indicating improved crypt survival. Crypt survival studies suggested an increase in precursor units or stem cells per crypt. Thus, investigation of the effects of radiation and AA-ORS on stem cell number was performed by incorporation of EdU using antibodies specific for intestinal stem cell markers and migration of daughter cells to the villi after proliferation. 2,4,36 At least three distinct crypt cell types have been hypothesized to represent intestinal stem cells (ISCs) 2 Each member of the population is thought to have a unique function, as they have distinct growth kinetics and sensitivity to radiation. 31 They are thought to dynamically switch from one type to another in response to inhibitory and stimulatory signals elicited by cytokines, hormones, or growth factors. 25 In contrast, slowly dividing intestinal epithelial stem cells (IESCs) [label-retaining cells (LRCs)] in the +4 crypt position contribute to homeostatic regenerative capacity, especially during recovery from injury. 33 These LRCs express various markers, such as Bmil, HopX, Lrigl, and / or Dclk1, and can transform into rapidly cycling IESCs in response to injury. 34 Although Bmi1 and HopX have been reported to preferentially mark +4 cells, Lgr5 can mark both types of cells. 15Lgr5+ISCs are required for intestinal regeneration after radiation injury. 35 Lgr5 - and Bmil are thought to be reserve cells that initiate regenerative responses after injury or radiation-induced damage. Studies have shown that activation of the Bmil-expressing stem cell pool results in the expression of Lgr5 + This indicates that cell loss is acceptable. 2,30 .
[0099] The amino acid formulation AA-ORS, which increases villus height, has important implications for disease states that are outside the scope of toxicity due to radiation or chemotherapy, such as those characterized by reduced villus height, such as Crohn's disease, celiac disease, malnutrition, and environmental enteropathy. This study shows how systematic selection of specific nutrients based on their beneficial effects on gut function can help improve in situ proliferation, maturation, and differentiation of intestinal stem cells, rendering functionally active long villus epithelial cells whose function and height are initially compromised by radiation (Figure 7). This study is also supported by the observation by Leibowitz et al. that bone marrow-derived stem cells do not play a significant role in repopulating the intestinal mucosa after high-dose irradiation [Leibowitz, BJ et al. Ionizing irradiation induces acute haematopoietic syndrome and gastrointestinal syndrome independently in mice. Nat Commun 5, 3494, doi:10.1038 / ncomms4494 (2014)]. Future studies should seek to determine the mechanisms by which these amino acids increase stem cell populations, increase their proliferation, decrease apoptosis, and eliminate malignant transformation. This study highlights the importance of carefully selecting different nutrients and individual amino acids to influence various stem cell populations, including hematopoietic stem cells.
[0100] <Stem and / or progenitor cells> The compositions and methods described herein can be used to increase survival, proliferation, and / or growth of stem and / or progenitor cells. The cells can be, for example, embryonic, pluripotent, or totipotent, and can be in vivo or in vitro.
[0101] Stem cells can usually differentiate into ectodermal, mesodermal, and endodermal cells. Pluripotent stem cells are undifferentiated cells that have the ability to differentiate into various cell types. Totipotent stem cells are undifferentiated cells that have the ability to differentiate into all cell types, which by definition means germ line transmission.
[0102] In one embodiment, the stem cells are mesenchymal stem cells that have the ability to differentiate into, for example, osteoblasts, chondrocytes, adipocytes, fibroblasts, smooth muscle cells, stromal cells, tenocytes, epithelial cells, neural cells, and vascular endothelial cells.
[0103] In one embodiment, the cells are embryonic stem (ES) cells, which can grow indefinitely in an undifferentiated state. Moreover, ES cells are totipotent, meaning they can generate all cells present in the body (bone, muscle, brain cells, etc.). ES cells are isolated from the inner cell mass (ICM) of developing mouse blastocysts [Evans et al., Nature 292:154-156, 1981; Martin et al., Proc. Natl. Acad. Sci. 78:7634-7636, 1981; Robertson et al., Nature 323:445-448, 1986]. Also, human cells with ES characteristics have been isolated from the endocyst cell mass (Thomson et al., Science 282:1145-1147, 1998) and developing germ cells (Shamblott et al., Proc. Natl. Acad. Sci. USA 95:13726-13731, 1998). Human and non-human primate embryonic stem cells have been produced (see U.S. Pat. No. 6,200,806, which is incorporated herein by reference).
[0104] In one embodiment, the cells are adult stem cells that self-renew to generate differentiated cells. Adult stem cells, also called somatic stem cells, are stem cells that maintain and repair tissues found in the body. These cells are, for example, bone marrow stem cells.
[0105] Somatic progenitor cells may also be utilized with the methods disclosed herein. Somatic progenitor cells may be isolated from a variety of sources using methods known to those skilled in the art. Somatic progenitor cells may be of ectodermal, mesodermal, or endodermal origin. Any somatic progenitor cells that can be obtained and maintained in vitro may be used according to the present methods. Such cells include cells of epithelial tissues such as the skin and the intestinal wall, embryonic cardiomyocytes, and neural progenitor cells [Stemple and Anderson, 1992, Cell 71:973-985]. Such cells also include pancreatic stem cells, umbilical cord blood stem cells, peripheral blood stem cells, and stem cells derived from adipose tissue.
[0106] In one embodiment, the stem cells further include pluripotent stem cells obtained by programming somatic cells. Somatic cell reprogramming is the process of converting the epigenetic state of differentiated somatic cells into a pluripotent state that can give rise to any cell type. Somatic cell reprogramming can be achieved, for example, by transferring a somatic cell nucleus into a donor oocyte, which is called somatic cell nuclear transfer (SCNT). Somatic cell reprogramming can also be achieved by direct reprogramming, for example, by simultaneous retroviral expression of four transcription factors Oct4, Sox2, Klf4, and C-myc, which are called induced pluripotent stem cells (iPSCs). These iPSCs share all the important characteristics of ES cells.
[0107] In another embodiment, other post-embryonic stem cells can be obtained from fetal liver, perinatal umbilical cord blood (UCB), human bone marrow or G-CSF stimulated peripheral blood from the 12th week after conception.
[0108] In certain embodiments, the stem cells are neural stem cells (NSCs), skin stem cells, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), tissue stem cells (e.g., muscle stem cells), mesodermal stem cells, organ stem cells (e.g., pancreatic stem cells and liver stem cells), or intestinal stem cells. In certain embodiments, the stem cells are adult stem cells, embryonic stem cells, cancer stem cells, neural stem cells (NSCs), skin stem cells, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), tissue stem cells (e.g., muscle stem cells), mesodermal stem cells, organ stem cells (e.g., pancreatic stem cells and liver stem cells), or intestinal stem cells.
[0109] In one embodiment, the cells are neural stem cells. In a non-limiting example, the cells are neural progenitor cells and / or glial progenitor cells. Undifferentiated neural stem cells differentiate into neuroblasts and glioblasts, giving rise to neurons and glial cells.
[0110] Neural stem and progenitor cells can participate in normal developmental patterns, including migration along established migratory pathways to disseminated CNS regions, and differentiation into multiple developmentally and regionally appropriate cell types in response to microenvironmental cues and non-destructive, non-tumorigenic dissemination with host precursors and their progeny.
[0111] Human NSCs have the ability to express foreign transgenes in vivo at their seeding sites, and therefore find use in the treatment of a variety of conditions including traumatic injuries to the spinal cord, brain, and peripheral nervous system, as well as in the treatment of degenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases, affective disorders including depression, stroke, and the like.
[0112] In one embodiment, the stem cell is a muscle stem cell. Adult vertebrate muscle tissue regenerates from reserve myoblasts called satellite cells. Satellite cells are distributed throughout muscle tissue and are mitotically quiescent in the absence of injury or disease. After recovery from injury or disease or in response to a stimulus for growth or hypertrophy, satellite cells re-enter the cell cycle, proliferate, and differentiate into multinucleated myotubes that form new myofibers. Myoblasts eventually produce replacement myofibers or fuse with existing myofibers, thereby increasing fiber circumference through the synthesis of contractile apparatus components. Myogenic criteria include myogenic proteins, including the intermediate filament protein desmin, and myogenic transcription factors MyoD, Myf-5, and Pax-7.
[0113] In one embodiment, the stem cells are hair follicle stem cells. The hair follicle bulge region is a rich and easily accessible source of actively growing multipotent adult stem cells. Nestin, a protein marker for neural stem cells, is also expressed in follicular stem cells and in their immediate progeny upon differentiation. Nestin-expressing hair follicle stem cells differentiate in vitro into, for example, neurons, glial cells, keratinocytes, and smooth muscle cells.
[0114] In one embodiment, the stem cells are pancreatic stem cells and pancreatic multipotent progenitor cells (PMP) cells. These cells can be isolated from tissues derived from pancreatic islets and pancreatic ducts and further developed, for example, into other PMP cells, neural cells or pancreatic cells. Pancreatic cells optionally include alpha cells, delta cells, beta cells, pancreatic exocrine cells, and pancreatic stellate cells. Alpha cells are mature glucagon-producing cells. In vivo, these cells are found in the pancreatic islets of the Islets of Langerhans. Beta cells are mature insulin-producing cells. In vivo, these cells are also found in the pancreatic islets of the Islets of Langerhans. Pancreatic stem cells are important in the treatment of diabetes, especially type I diabetes, to provide beta cells.
[0115] In one embodiment, the stem cells are bone marrow stem cells. Bone marrow stem cells are cells generated in bone marrow and can differentiate into cells of various body tissues. Bone marrow stem cells can also restore lost functions of tissues by differentiating into cells of the tissue under the influence of differentiation inducers. Bone marrow stem cells include bone marrow mesenchymal stem cells, which can differentiate into bone cells, cartilage cells, adipocytes, muscle cells, tendon cells, or bone marrow stromal cells, and hematopoietic stem cells, which can differentiate into blood cells, such as red blood cells and white blood cells.
[0116] In one embodiment, the stem cells are of the gastrointestinal tract. Epithelial cells are found in the lining of the gastrointestinal tract. The turnover of these cells is a constant process under normal homeostasis and increases after injury. Multipotent stem cells regulate this process by generating all gastrointestinal epithelial cell lineages, and even the entirety of the intestinal crypts and gastric glands. These stem cells are located at the bottom of the intestinal crypts and include the fast-cycling crypt base columnar cells (CBC) and the more inactive "+4" cells above the mammalian Paneth cells.
[0117] At least three distinct crypt cell types are set to represent intestinal stem cells (ISCs). Each member of the population is thought to have a unique function, as they have clearly distinct proliferation kinetics and sensitivity to radiation. They are thought to dynamically switch from one type to another in response to inhibitory and stimulatory signals triggered by cytokines, hormones or growth factors. In contrast, slower dividing intestinal epithelial stem cells (IESCs) [label-retaining cells (LRCs)] in the "+4 crypt position" contribute to homeostatic regenerative capacity, especially during recovery from injury. These LRCs express various markers, such as Bmil, HopX, Lrigl, and / or Dclk1, and can transform into rapidly dividing IESCs in response to injury. Bmi1 and HopX have been reported to preferentially mark +4 cells. Lgr5 is essential for intestinal regeneration after gastrointestinal injury caused by radiation and / or chemotherapy. + ISC is required. - Bmil and Bmil are believed to be reserve cells that initiate a regenerative response after injury or radiation-induced injury. Similarly, the formulations can be used in asymptomatic disease states such as environmental enteropathy, which is associated with increased intestinal permeability, increased local and systemic inflammation, and reduced villus height. Subjects with environmental enteropathy experience chronic malnutrition, which is a secondary effect of malabsorption of nutrients and minerals.
[0118] <Compositions for promoting proliferation and / or growth of stem cells and / or progenitor cells, comprising compositions for wound healing, compositions for treating diseases related to skin conditions, lung diseases, mucosal barrier conditions and mucosal barrier functions, and compositions for treating gastrointestinal mucosal damage> In one aspect, therapeutic compositions are provided for promoting survival, proliferation, and / or growth of stem and / or progenitor cells. Described herein are compositions for treating and improving a disease or condition associated with mucosal barrier function (e.g., wound healing), treating a skin condition (e.g., atopic dermatitis, psoriasis, pressure sores, or a condition associated with skin aging), treating a lung disease (e.g., asthma), improving mucosal barrier function, and / or treating damage to the gastrointestinal mucosa in a subject in need thereof.
[0119] In one embodiment, the therapeutic composition comprises, consists essentially of, or consists of one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, serine, and derivatives thereof, optionally including, for example, a pharma- ceutically acceptable carrier, adjuvant, and / or additional active agent. In one embodiment, the therapeutic composition comprises, consists essentially of, or consists of one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, serine, and derivatives thereof, optionally including, for example, a pharma- ceutically acceptable carrier, adjuvant, and / or additional active agent. In certain embodiments, the composition is sterilized.
[0120] In one embodiment, the total osmolality of the composition is from about 100 mosm to about 280 mosm, or any value therebetween. Preferably, the total osmolality is from about 150 mosm to about 280 mosm. In another embodiment, the total osmolality of the composition is any value below about 280 mosm.
[0121] The pH of the composition may be, for example, about 2.5 to about 8.5. In certain embodiments, the pH of the composition is about 2.5 to about 6.5, about 3.0 to about 6.0, about 3.5 to about 5.5, about 3.9 to about 5.0, or about 4.2 to about 4.6. In other embodiments, the pH of the composition is about 6.5 to about 8.5, about 7.0 to about 8.0, or about 7.2 to about 7.8.
[0122] In certain embodiments, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, serine, and derivatives thereof. In certain embodiments, the composition comprises one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, and aspartic acid. The composition preferably comprises one or more free amino acids selected from the group consisting of threonine, valine, serine, tyrosine, and tryptophan. In certain embodiments, the composition comprises two or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises three or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises four or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine. In certain embodiments, the composition comprises threonine, valine, tyrosine, tryptophan, and aspartic acid. In certain embodiments, the composition comprises free amino acids consisting of threonine, valine, tyrosine, tryptophan, and serine.
[0123] When these amino acids are present in the composition, acceptable concentrations are, for example, about 0.4 to about 1.5, about 0.7 to about 1.3, or about 0.9 to about 1.1 grams / liter for threonine, about 0.7 to about 1.7, about 0.9 to about 1.5, or about 1.1 to about 1.3 grams / liter for valine, about 0.6 to about 1.6, about 0.8 to about 1.4, or about 1.0 to about 1.2 grams / liter for serine, about 0.05 to about 0.4, or about 0.1 to about 0.3 grams / liter for tyrosine, and about 1.1 to about 2.1, about 1.3 to about 1.9, or about 1.5 to about 1.7 grams / liter for tryptophan. In certain embodiments, the therapeutic composition comprises threonine (about 1.0 grams / liter), valine (about 1.2 grams / liter), serine (about 1.1 grams / liter), tyrosine (about 0.2 grams / liter), and tryptophan (about 1.6 grams / liter). In one embodiment, the composition does not comprise serine.
[0124] In a further embodiment, the composition comprises or consists essentially of one free amino acid selected from threonine, valine, tyrosine, and tryptophan, and / or derivatives thereof. In a further embodiment, the therapeutic composition comprises or consists essentially of threonine as a free amino acid. The therapeutic composition can also comprise or consist essentially of valine as a free amino acid. The therapeutic composition also comprises or consists essentially of tyrosine as a free amino acid. The therapeutic composition comprises or consists essentially of tryptophan as a free amino acid. Furthermore, the therapeutic composition comprises or consists essentially of aspartic acid as a free amino acid. In a particular embodiment, the composition comprises serine as a free amino acid.
[0125] In another embodiment, the composition also comprises or consists essentially of two free amino acids selected from the group consisting of threonine, valine, serine, tyrosine, tryptophan and aspartic acid, the two free amino acids including a combination of threonine and valine; a combination of threonine and serine; a combination of threonine and tyrosine; a combination of threonine and tryptophan; a combination of valine and serine; a combination of valine and tyrosine; a combination of valine and tryptophan; a combination of serine and tyrosine; a combination of serine and tryptophan; a combination of tyrosine and aspartic acid; a combination of serine and aspartic acid; a combination of valine and aspartic acid; a combination of threonine and aspartic acid; a combination of tryptophan and aspartic acid; and a combination of tyrosine and tryptophan.
[0126] In another embodiment, the composition comprises or consists essentially of three free amino acids selected from the group consisting of threonine, valine, serine, tyrosine, tryptophan and aspartic acid, wherein the three free amino acids are a combination of threonine, valine and serine; a combination of threonine, valine and tyrosine; a combination of threonine, valine and tryptophan; a combination of threonine, serine and tyrosine; a combination of threonine, serine and tyrosine; a combination of threonine, serine and tryptophan; a combination of threonine, tyrosine and tryptophan; a combination of valine, serine and tyrosine; a combination of valine, serine and tryptophan. combinations of valine, tyrosine and tryptophan; combinations of serine, tyrosine and tryptophan; combinations of threonine, valine and aspartic acid; combinations of threonine, serine and aspartic acid; combinations of threonine, tyrosine and aspartic acid; combinations of threonine, tryptophan and aspartic acid; combinations of valine, serine and aspartic acid; combinations of valine, tyrosine and aspartic acid; combinations of valine, tryptophan and aspartic acid; combinations of serine, tyrosine and aspartic acid; combinations of serine, tryptophan and aspartic acid; combinations of tyrosine, tryptophan and aspartic acid.
[0127] In another embodiment, the composition comprises or consists essentially of four free amino acids selected from the group consisting of threonine, valine, serine, tyrosine, tryptophan, and aspartic acid, the four free amino acids being a combination of threonine, valine, serine, and tyrosine; a combination of threonine, valine, serine, and tryptophan; a combination of threonine, valine, tyrosine, and tryptophan; a combination of threonine, serine, tyrosine, and tryptophan; a combination of valine, serine, tyrosine, and tryptophan; a combination of threonine, valine, serine, and aspartic acid. combinations of threonine, valine, tyrosine and aspartic acid; combinations of threonine, valine, tryptophan and aspartic acid; combinations of threonine, serine, tyrosine and aspartic acid; combinations of threonine, serine, tryptophan and aspartic acid; combinations of threonine, tyrosine, tryptophan and aspartic acid; combinations of valine, serine, tyrosine and aspartic acid; combinations of valine, serine, tryptophan and aspartic acid; combinations of valine, tyrosine, tryptophan and aspartic acid; combinations of serine, tyrosine, tryptophan and aspartic acid; combinations of serine, tyrosine, tryptophan and aspartic acid.
[0128] In another embodiment, the composition comprises or consists essentially of five free amino acids selected from the group consisting of threonine, valine, serine, tyrosine, tryptophan and aspartic acid, the five free amino acids including: a combination of threonine, valine, serine, tyrosine and tryptophan; a combination of threonine, valine, serine, tyrosine and aspartic acid; a combination of threonine, valine, serine, tryptophan and aspartic acid; a combination of threonine, valine, tyrosine, tryptophan and aspartic acid; a combination of threonine, valine, tyrosine, tryptophan and aspartic acid; a combination of threonine, serine, tyrosine, tryptophan and aspartic acid.
[0129] In another embodiment, the composition comprises or consists essentially of the following free amino acids: threonine, valine, serine, tyrosine, tryptophan, and aspartic acid.
[0130] In certain embodiments, the compositions can include natural amino acids and derivatives that can retain substantially the same or better activity as the natural amino acids in improving stem cell and / or progenitor cell survival, proliferation, and / or growth. In certain embodiments, the compositions can include natural amino acids and derivatives that can retain substantially the same or better activity as the natural amino acids in improving wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or conditions associated with skin aging), treating lung disease (e.g., asthma), improving mucosal barrier function, and / or treating GI mucosa damage in subjects in need of treatment. The derivatives can be, for example, enantiomers, including both D and L forms of the amino acids. The derivatives can be, for example, iodotyrosine, or norvaline. Other amino acid derivatives can include, for example, norleucine, ornithine, penicillamine, pyroglutamine derivatives, or other derivatives can include alanine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, isoleucine, leucine, lysine, methionine, proline, phenalaline, serine, threonine, tryptophan, or valine. In certain embodiments, the amino acid derivative is a derivative of threonine, valine, tyrosine, tryptophan, aspartic acid, or serine. Other amino acid derivatives can include, but are not limited to, those synthesized by acylation, methylation, and / or halogenation of amino acids. These include, for example, β-methyl amino acids, C-methyl amino acids, and N-methyl amino acids.
[0131] In some specific embodiments, the compositions of the present disclosure do not include one or more amino acids selected from the group consisting of serine, lysine, glycine, isoleucine, and asparagine, or, in certain embodiments, if these amino acids are present in the composition, they are not present in an amount that inhibits the survival, proliferation, and / or growth of stem and / or progenitor cells.
[0132] In certain specific embodiments, the compositions of the present disclosure do not contain, or contain a negligible amount of, one of the amino acids selected from the group consisting of serine, lysine, glycine, aspartic acid, isoleucine, and asparagine. In further embodiments, the therapeutic composition does not contain lysine as a free amino acid, or the therapeutic composition does not contain glycine as a free amino acid, or the therapeutic composition does not contain aspartic acid as a free amino acid, or the therapeutic composition does not contain isoleucine as a free amino acid, or the therapeutic composition does not contain asparagine as a free amino acid.
[0133] In some embodiments, the therapeutic composition does not include any two of the free amino acids selected from the group consisting of serine, lysine, glycine, isoleucine, and asparagine, including a combination of lysine and glycine; a combination of lysine and aspartic acid; a combination of lysine and isoleucine; a combination of lysine and asparagine; a combination of glycine and aspartic acid; a combination of glycine and isoleucine; a combination of glycine and asparagine; a combination of aspartic acid and isoleucine; a combination of aspartic acid and asparagine; and a combination of isoleucine and asparagine.
[0134] In other embodiments, the composition does not contain any three of the free amino acids selected from the group consisting of serine, lysine, glycine, isoleucine and asparagine, and the three include a combination of lysine, glycine and aspartic acid; a combination of lysine, glycine and isoleucine; a combination of lysine, glycine and asparagine; a combination of lysine, aspartic acid and isoleucine; a combination of lysine, aspartic acid and asparagine; a combination of lysine, isoleucine and asparagine; a combination of glycine, aspartic acid and isoleucine; a combination of glycine, aspartic acid and asparagine; a combination of glycine, isoleucine and asparagine; a combination of aspartic acid, isoleucine and asparagine;
[0135] In further embodiments, the composition does not include any four of the free amino acids selected from the group consisting of serine, lysine, glycine, aspartic acid, isoleucine, and asparagine, including a combination of lysine, glycine, aspartic acid, and isoleucine; a combination of lysine, glycine, aspartic acid, and asparagine; a combination of lysine, aspartic acid, isoleucine, and asparagine; a combination of lysine, glycine, isoleucine, and asparagine; a combination of glycine, aspartic acid, isoleucine, and asparagine.
[0136] In certain embodiments, the compositions of the present disclosure are free of lysine, glycine, aspartic acid, isoleucine, and asparagine. In another particular embodiment, the compositions are free of or contain negligible amounts of serine, lysine, glycine, aspartic acid, isoleucine, and asparagine. In one embodiment, the compositions are free of glutamine and / or methionine, and any di-peptide, oligo-peptide, or polypeptide or protein that can be hydrolyzed to glutamine and / or methionine.
[0137] In some specific embodiments, the therapeutic composition may include lysine, where the total concentration of lysine is less than 300 mg / L, less than 100 mg / L, less than 50 mg / L, less than 10 mg / L, less than 5 mg / L, less than 1 mg / L, less than 0.5 mg / L, or less than 0.01 mg / L. The therapeutic composition may include aspartic acid, where the total concentration of aspartic acid is less than 300 mg / L, less than 100 mg / L, less than 50 mg / L, less than 10 mg / L, less than 5 mg / L, less than 1 mg / L, less than 0.5 mg / L, or less than 0.01 mg / L. The therapeutic composition may include glycine, where the total concentration of glycine is less than 300 mg / L, less than 100 mg / L, less than 50 mg / L, less than 10 mg / L, less than 5 mg / L, less than 1 mg / L, less than 0.5 mg / L, or less than 0.01 mg / L. The therapeutic composition may further comprise isoleucine, where the total concentration of isoleucine is less than 300 mg / L, less than 100 mg / L, less than 50 mg / L, less than 10 mg / L, less than 5 mg / L, less than 1 mg / L, less than 0.5 mg / L, or less than 0.01 mg / L. The therapeutic composition may further comprise asparagine, where the total concentration of asparagine is less than 10 mg / L, less than 5 mg / L, less than 1 mg / L, less than 0.5 mg / L, or less than 0.01 mg / L.
[0138] In alternative embodiments, the composition may comprise free amino acid glutamine and, optionally, one or more glutamine-containing dipeptides, and the combined concentration of the free amino acid glutamine and the glutamine-containing dipeptides is less than 300 mg / l or any concentration less than 300 mg / l, such as less than 100 mg / l, less than 50 mg / l, less than 10 mg / l, less than 5 mg / l, less than 1 mg / l, less than 0.5 mg / l, or less than 0.01 mg / l. In certain embodiments, the composition may comprise free amino acid glutamine and, optionally, one or more glutamine-containing peptides, and the combined concentration of the free amino acid glutamine and the glutamine-containing dipeptides is less than 300 mg / l or any concentration less than 300 mg / l, such as less than 100 mg / l, less than 50 mg / l, less than 10 mg / l, less than 5 mg / l, less than 1 mg / l, less than 0.5 mg / l, or less than 0.01 mg / l.
[0139] In another alternative embodiment, a therapeutic composition may comprise the free amino acid methionine and, optionally, one or more methionine-containing dipeptides, where the combined concentration of the free amino acid methionine and the methionine-containing dipeptides is less than 300 mg / l or may be any concentration less than 300 mg / l, such as less than 100 mg / l, less than 50 mg / l, less than 10 mg / l, less than 5 mg / l, less than 1 mg / l, less than 0.5 mg / l, or less than 0.01 mg / l. In a particular embodiment, a composition may comprise the free amino acid methionine and, optionally, one or more methionine-containing peptides, where the combined concentration of the free amino acid methionine and the methionine-containing dipeptides is less than 300 mg / l or may be any concentration less than 300 mg / l, such as less than 100 mg / l, less than 50 mg / l, less than 10 mg / l, less than 5 mg / l, less than 1 mg / l, less than 0.5 mg / l, or less than 0.01 mg / l.
[0140] In certain embodiments, the composition also includes additives (e.g., nutrients, electrolytes, vitamins, minerals, etc.). In certain embodiments, the composition includes iron or zinc. In certain embodiments, the therapeutic composition includes, for example, Na + ;K + ;HCO 3 - ;CO 3 2- ;Ca 2+ ;Mg 2+ ;Fe 2 ;Cl - For example, H 2 PO 4 - , H.P.O. 4 2- , P.O. 4 3- In another embodiment, the composition comprises one or more electrolytes selected from HCO 3 - or CO 3 2- In another alternative embodiment, the composition does not include HCO 3 - and CO 3 2- in a total concentration of less than 5 mg / l, or less than 5 mg / l. In certain embodiments, the composition does not include electrolytes. For example, in certain embodiments, the composition includes Na + ;K + ;HCO 3 - ;CO 3 2- ;Ca 2+ ;Mg 2+ ;Fe 2 ;Cl - For example, H 2 PO 4 - , H.P.O. 4 2- , P.O. 4 3- and the like; zinc; iodine; copper; iron; selenium; chromium; and molybdenum, or none of them.
[0141] In certain embodiments, the composition does not include one or more components selected from: oligosaccharides, polysaccharides, and carbohydrates; oligopeptides or polypeptides or proteins; lipids; small, medium and / or long chain fatty acids; and / or foods containing one or more of the above nutrients. In certain embodiments, the composition does not include glucose or sucrose.
[0142] In one embodiment, to buffer the composition of the present disclosure, H 2 PO 4 - , H.P.O. 4 2- , and P.O. 4 3- In one embodiment, the therapeutic composition contains phosphate ions such as HCO as a buffer. 3 - or CO 3 2- In another embodiment, the therapeutic composition uses HCO as a buffer. 3 - or CO 3 2- Do not use.
[0143] In certain embodiments, the composition comprises valine, threonine, tyrosine, electrolytes, Na + (approximately 10 mmol to 60 mmol), and K + (about 1 mmol to 20 mmol). In certain embodiments, the composition comprises a buffer.
[0144] <Treatment with stem and / or progenitor cells for wound healing, treatment of skin conditions and pulmonary diseases, improvement of mucosal barrier function, and / or treatment of GI mucosal injury> Described herein are amino acid compositions as methods for treating gastrointestinal, pulmonary and skin disorders. The disclosure provides compositions and methods for improving the survival, proliferation and / or growth of stem cells and / or progenitor cells. The disclosure provides compositions and methods for treating and improving diseases or conditions associated with mucosal barrier function (e.g. wound healing), skin conditions (e.g. atopic dermatitis, psoriasis, pressure sores, or conditions associated with skin aging), pulmonary diseases (e.g. asthma), improving mucosal barrier function, and / or treating damage to the gastrointestinal mucosa in a subject in need thereof. The number of stem cells and / or progenitor cells can be increased by increasing the survival, proliferation and / or growth of the cells. In one embodiment, the method includes exposing the stem cells and / or progenitor cells to a composition of the disclosure. The stem cells and / or progenitor cells can be exposed to a cultured composition, an ex vivo generated composition, an in situ generated composition, or an in vivo generated composition after being administered to the subject, implanted, or delivered.
[0145] The subject may be, for example, a human in which enhanced survival, proliferation and / or growth of stem and / or progenitor cells is required. The subject may be, for example, a human with a disease or condition in need of treatment. In addition to humans, the subject may be any species of animal, including, but not limited to, domestic and laboratory animals such as dogs, cats, mice, rats, guinea pigs and hamsters; livestock such as horses, cows, pigs, sheep, goats, ducks, geese and chickens; other primates such as apes, chimpanzees, orangutans and monkeys; fish; amphibians such as frogs and salamanders; reptiles such as snakes and lizards; foxes, camels, bears, antelopes, llamas, weasels, rabbits, minks, beavers, ermines, otters, sables, seals, coyotes, chinchillas, deer, musk rats, opossums and other animals.
[0146] In one embodiment, the method results in increased survival, proliferation, and / or growth of stem and / or progenitor cells. In certain embodiments, the method results in an improvement in the condition of a subject having a disease or condition associated with mucosal barrier function, such as, for example, a wound, a skin condition (e.g., atopic dermatitis, psoriasis, pressure sores, or a condition associated with skin aging), a pulmonary disease (e.g., asthma), mucosal barrier function, and / or damage to the gastrointestinal mucosa.
[0147] In one embodiment, the method comprises introducing a composition of the invention into stem and / or progenitor cells in culture to promote survival, proliferation, and / or growth of the stem and / or progenitor cells. The composition can be used to increase the amount of cells used to treat various diseases and conditions.
[0148] In one embodiment, the present disclosure provides a method for improving the therapeutic outcome of transplanted stem cells, comprising administering a composition of the present disclosure in conjunction with stem cell transplantation. The administration of the composition can be at or near the site of transplantation of the targeted stem cells and / or progenitor cells in a human or non-human animal. In certain embodiments, the present invention provides a method for treating a subject in need of treatment of a disease or condition associated with mucosal barrier function, e.g., wounds, treatment of a skin condition (e.g., atopic dermatitis, psoriasis, pressure sores, or conditions associated with skin aging), treatment of a pulmonary disease (e.g., asthma), improvement of mucosal barrier function, and / or treatment of damage to the GI mucosa, comprising administering to the subject a composition as described herein.
[0149] In one embodiment, a subject receiving stem and / or progenitor cells can be immunosuppressed using immunosuppressive drugs such as cyclosporine or using locally applied immunosuppressants via local immunosuppression techniques, although such immunosuppression is not necessarily a requirement in certain immune privileged tissues, such as brain and eye tissue.
[0150] In certain embodiments, the administered stem and / or progenitor cells are autologous in nature and prepared from the recipient's own tissue. In such cases, stem cell progeny can be generated from dissociated or isolated tissue and expanded in vitro using the compositions of the present disclosure. Once expanded to an appropriate cell number, the cells are harvested and ready to be administered to the subject's affected tissue.
[0151] In one embodiment, the disclosure provides a method of promoting stem cell proliferation and differentiation in a subject in need thereof, the method comprising: identifying the subject; and administering to the subject an effective amount of a composition comprising, consisting essentially of, or consisting of one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine, and optionally including a pharmaceutically acceptable carrier, adjuvant, and / or other active agent, the composition having a total osmolality of about 100 mosm to about 280 mosm and a pH of about 2.5 to about 6.5. In certain embodiments, the present disclosure provides a method for treating and improving a disease or condition associated with mucosal barrier function (e.g., wound healing), treating a skin condition (e.g., atopic dermatitis, psoriasis, pressure sores, or conditions associated with skin aging), treating a pulmonary disease (e.g., asthma), improving mucosal barrier function, and / or treating damage to the GI mucosa in a subject in need thereof, the method comprising identifying the subject and administering to the subject an effective amount of a composition comprising, consisting essentially of, or consisting of one or more free amino acids selected from the group consisting of threonine, valine, tyrosine, tryptophan, aspartic acid, and serine, and optionally including a pharmaceutically acceptable carrier, adjuvant, and / or other active agent, the composition having a total osmolality of about 100 mosm to about 280 mosm and a pH of about 2.5 to about 6.5.
[0152] In another embodiment, the compositions and methods of the present disclosure can be used to overcome bone marrow suppression that is a secondary effect of drugs, chemicals, and viral or bacterial infections of unknown etiology.
[0153] In certain embodiments, the present disclosure can be used to promote proliferation and growth of stem and / or progenitor cells in diseases and conditions including, but not limited to, malignancies; Pains cell deficiency; hypopituitarism; celiac disease, such as celiac disease unresponsive to a gluten-free diet; tropical sprue; radiation-related ischemia; drug-induced villous atrophy, such as villous atrophy induced by neomycin and azathioprine; severe food hypersensitivity; congenital Crohn's disease; autoimmune enteropathy; enteritis; hepatitis; intestinal cancer intestinal lymphoma; type 1 diabetes; allergies; ocular conditions, such as corneal lacerations; eosinophilic gastroenteritis; viral gastroenteritis, and immune deficiency syndromes.
[0154] In some embodiments, the present disclosure can be used to promote stem cell proliferation and differentiation in conditions and diseases induced by viral, fungal or bacterial infections, such as myelosuppression caused by viral, fungal or bacterial infections. For example, the compositions and methods can be used to treat patients with reduced platelet counts, such as those caused by the Dengue virus.
[0155] The compositions described herein can also be used to treat or ameliorate symptoms of deficiencies caused by, for example, a neurodegenerative disease, a traumatic injury, a neurotoxic injury, an ischemic, developmental disorder, a disorder affecting vision, a spinal cord injury or disease, a demyelinating disease, an autoimmune disease, an infectious disease, an inflammatory disease, or a systemic disease.
[0156] In certain embodiments, the transplanted stem cells are capable of proliferating, migrating to areas of tissue damage, and / or differentiating in a tissue-specific manner and functioning to alleviate the defect.
[0157] In one embodiment, the methods and compositions according to the present disclosure are particularly useful for patients who have been exposed to radiation or who are undergoing radiation, chemotherapy and / or proton beam therapy.
[0158] In another aspect, the disclosure provides a method of treating injury to the GI tract (e.g., small intestinal mucosa, esophagus, stomach, large intestine, etc.), injury to the genitourinary tract, or injury to an organ with a mucosal lining in a subject in need of such treatment comprising administering to the subject a composition described herein. In another aspect, the disclosure provides a method of treating an injury to a mucosal barrier associated condition in a subject in need of such treatment comprising administering to the subject a composition described herein.
[0159] The compositions of the present disclosure can be used to treat or improve any disease or condition that requires proliferation and / or growth of stem cells and / or progenitor cells. In certain embodiments, the compositions and methods of the present disclosure can be used to treat or improve small intestinal damage caused by radiation by promoting proliferation of stem cells. In another specific embodiment, the present disclosure can be used to treat or improve small intestinal damage caused by radiation therapy, particularly pelvic and abdominal radiation therapy. In certain embodiments, radiation therapy is a method of treatment for cancer. The present disclosure may also be used to promote stem cell proliferation to treat or ameliorate damage caused to the small intestine by chemotherapeutic agents including, but not limited to, cisplatin, 5-fluorouracil (5-FU), hydroxyurea, etoposide, arabinoside, 6-mercaptopurine, 6-thioguanine, fludarabine, methohexate, steroids, and / or combinations thereof. Exemplary chemotherapeutic agents include antiestrogens (e.g., tamoxifen, raloxifene, and megestrol), LHRH agonists (e.g., gocycline and leuprolide), antiandrogens (e.g., flutamide and bicalutamide), photodynamic therapy agents (e.g., vertoporphine (BPD-MA), phthalocyanines, photosensitizer Pc4, and demethoxy-hypocrelin A (2BA-2-DMHA)), nitrogen mustards (e.g., cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (e.g., carmustine (BCNU) and lomustine (CCNU)), alkylsulfonates (e.g., busulfan and tresulfan), triazenes (e.g., dacarbazine, temozolomide), platinum-containing compounds (e.g., cisplatin, carboplatin, , oxaliplatin), vinca alkaloids (e.g., vincristine, vinblastine, vindesine, and vinorelbine), taxoids (e.g., paclitaxel, or nanoparticle albumin-bound paclitaxel (ABRAXANE), docosahexaenoic acid-bound paclitaxel (DHA-paclitaxel, taxoplexin), polyglutamate-bound paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX, and other paclitaxel equivalents), tumor-activated prodrug (TAP) ANG1005 (angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2 recognition peptide EC-1), and glucose-bound paclitaxel, such as 2'-paclitaxel methyl 2-glucopyranosyl succinate;docetaxel, taxol), epipodophyllins (e.g., etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoterinotecan, irinotecan, crisnatol, mitomycin C), antimetabolites, DHFR inhibitors (e.g., methotrexate, dichloromethotrexate, trimetrexate, edatrexate), IMP dehydrogenase inhibitors (e.g., mycophenolic acid, tiazofurin, ribavirin, and EICAR), ribonucleotide reductase inhibitors (e.g., hydroxyurea and deferoxamine), uracil analogs (e.g., 5-fluorouracil (5-FU), floxuridine, doxifluridine, latitrexed, tegafur-uracil, cacipecitabine), protease inhibitor ... Phosphorus analogues (e.g., mercaptopurine and thioguanine), vitamin D3 analogues (e.g., EB1089, CB1093 and KH1060), isoprenylation inhibitors (e.g., lovastatin), dopaminergic neurotoxins (e.g., 1-methyl-4-phenylpyridinium ion), cell cycle inhibitors (e.g., staurosporine), actinomycins (e.g., actinomycin D, dactinomycin), bleomycins (e.g., bleomycin A2, bleomycin B2, peplomycin), anthracyclines (e.g., daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone), MDR inhibitors (e.g., verapamil), Ca; 2+ ATPase inhibitors (e.g., thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors (e.g., axitinib (AG013736)), bosutinib (SKI-606), cediranib (RECENTIN®, AZD2171), dasatinib (SPRYCEL®, BMS-354825), erlotinib (TARCEVA®), gefitinib (IRESSA®), imatinib (Gleevec®, CGP57148B, STI-571), lapatinib (TYKERB (R), TYVERB®), lestaurtinib (CEP-70), neratinib (HKI-272), nilotinib (TASIGNA®), semaxanib (semaxanib, SU5416), sunitinib (SUTENT®, SU11248), toceranib (PALLADIA®), vandetanib (ZACTIMA®, ZD6474), vatalanib (PTK787, PTK / ZK), trastuzumab (HERCEPTIN®), bevacizumab (AVASTIN®), rituximab (RITUXAN®), cetuximab (ERBITUX®), panitumumab (VECTIBIX®), ranibizumab (Lucentis®), nilotinib (TASIGNA®), sorafenib (NEXAVAR®), everonib (AFINITOR®), alemtuzumab (CAMPATH®), gemtuzumab ozogamicin (MYLOTARG®), temsirolimus (TORISEL®), ENMD-2076, PCI-32765, AC2 20, dovitinibractate (TKI258, CHIR-258), BIBW2992 (TOVOK®), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF1120 (VARGATEF®), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184,XL-647, and / or XL228), proteasome inhibitors (e.g., bortezomib (VELCADE), mTOR inhibitors (e.g., rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZenecca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI), oblimisen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbazine, prednisolone, dexamethasone, campatecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurocidin, leurosine, chlorambucil, trabectin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethylmethylamine.
[0160] In certain embodiments, the present disclosure can be used to promote stem cell survival and proliferation for the treatment or amelioration of diseases involving damage to the small intestine, including, but not limited to, inflammatory bowel disease (IBD), colitis, duodenal ulcers, Crohn's disease, and / or celiac disease (also known as celiac disease). The present disclosure can be used to treat or ameliorate damage to the small intestine due to pathogenic infections caused by viral, bacterial, fungal or other microbial infections.
[0161] In one embodiment, the stem cells and / or progenitor cells are exposed to radiation before treatment with the compositions of the present disclosure. In another embodiment, the stem cells and / or progenitor cells will be exposed to radiation after treatment with the compositions of the present disclosure. Radiation can be administered to the cells for, for example, 1 minute, 5 minutes, 30 minutes, 1 hour, 6 hours, 12 hours, 1 day, 5 days, 7 days, 14 days, 30 days, 60 days, 3 months, 6 months, 1 year, 2 years, or 3 years or more before or after treating the cells with the compositions described herein. The dose of radiation can be, for example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 120, or 150 Gy.
[0162] In one embodiment, the present disclosure can be used in the context of bone marrow transplantation. Bone marrow stem and / or progenitor cells can be treated in vivo or ex vivo with the compositions of the present disclosure. Such treatment enhances cell survival, proliferation, and / or growth.
[0163] In another embodiment, the present disclosure can be used in the context of Prochimal, an allogeneic stem cell therapy based on mesenchymal stem cells (MSCs) derived from the bone marrow of adult donors, for the management of acute graft-versus-host disease in children. The survival, proliferation, and / or growth of MSCs can be enhanced by contacting them in vitro or ex vivo with a composition of the present disclosure.
[0164] In another embodiment, the compositions and methods of the present disclosure can be used for cardiac treatment. Stem cell therapy for the treatment of myocardial infarction often utilizes autologous bone marrow stem cells, but other types of adult stem cells, such as adipose tissue-derived stem cells, can also be used. In one embodiment, stem cell therapy can be used to regenerate cardiac tissue and reverse the tissue loss that underlies the development of heart failure after cardiac injury.
[0165] In another embodiment, the compositions and methods of the present disclosure can be used for the formation and proliferation of blood cells. Fully mature human red blood cells can be generated ex vivo by hematopoietic stem cells (HSCs), the precursors of red blood cells. In this process, HSCs can be expanded together with stromal cells to create an environment similar to the conditions of bone marrow, the natural site of red blood cell proliferation. In using the compositions of the present disclosure, the stem cells can be induced to complete their terminal differentiation into red blood cells by adding the growth factor erythropoietin. The compositions and methods can also be used to expand the population of red blood cells, white blood cells, and / or platelets, for example, to improve oxygen carrying capacity (such as for athletes), the immune system (including treatment of immune deficiencies), and improve clotting.
[0166] In another embodiment, embryonic stem cells treated with the compositions of the present disclosure can be used to regrow cochlear hair.
[0167] In another embodiment, stem cells processed according to the present disclosure can be used to treat blindness and visual impairment, hi a specific embodiment, the compositions and methods are used to treat corneal lacerations.
[0168] In another embodiment, the present disclosure can be used to enhance the success of tissue transplants, including transplants of insulin-producing pancreatic beta cells. These cells can be prepared, for example, from embryonic stem cells differentiated into beta cells. These cells can be treated in vivo or ex vivo with the compositions of the present disclosure.
[0169] In another aspect, the disclosure provides a method of treating and / or promoting wound healing in a subject in need thereof, the method comprising administering to said subject a composition described herein. In certain embodiments, the disclosure provides a method of treating a wound in a subject in need thereof, the method comprising administering to said subject a composition described herein. In certain embodiments, the disclosure provides a method of treating a wound or burn in a subject in need thereof, the method comprising administering to said subject a composition described herein. In certain embodiments, the disclosure provides a method of treating a burn in a subject in need thereof, the method comprising administering to said subject a composition described herein. In certain embodiments, the wound is a partial thickness wound or a full thickness wound. In certain embodiments, the burn is a partial thickness burn or a full thickness burn.
[0170] The present disclosure may also be utilized in the context of wound healing. In adults, wound tissue is most frequently replaced by scar tissue, characterized by disorganized collagen structure, loss of hair follicles, and irregular vascular structure. In one embodiment, stem cell "seeds" are located inside the tissue layer within the wound bed, allowing the stem cells to stimulate differentiation of tissue layer cells. This method can be significantly improved by contacting the wound with a composition of the present disclosure, with or without the addition of stem cells. In certain embodiments, the composition is applied to the skin. In certain embodiments, the composition is administered to stem cells and / or progenitor cells.
[0171] In other embodiments, the compositions and methods described herein are useful, for example, in cosmetic applications where revitalization of various layers of the skin and / or underlying tissue is desired. This revitalization can be supported, for example, by improving the survival, proliferation, and / or growth of stem cells and / or progenitor cells. This revitalization can be supported, for example, by treating diseases or conditions related to mucosal barrier function (e.g., wounds), skin conditions (e.g., atopic dermatitis, psoriasis, pressure sores, or conditions related to skin aging), lung diseases (e.g., asthma), diseases or conditions related to mucosal barrier function, and / or damage to the gastrointestinal mucosa.
[0172] In this embodiment, the method of the present disclosure generally comprises the step of topically applying a therapeutically effective amount of the composition to the skin (e.g., epidermis) of a patient in need of skin (e.g., epidermal) treatment. In one embodiment, the composition is applied to the face.
[0173] The present invention provides compositions and methods for combating skin aging, including, for example, treating the appearance of wrinkles, fine lines, and other forms of undesirable skin texture. By applying the compositions to the dermal and / or epidermal layers of the skin, the skin's form, strength, and function are improved. In certain embodiments, the compositions and methods described herein are useful in cosmetic applications, for example, where revitalization of various layers of the skin and / or underlying tissues is desired.
[0174] In another aspect, the disclosure provides a method of treating and / or preventing a skin condition (e.g., atopic dermatitis, psoriasis, or a condition associated with skin aging) in a subject in need thereof, the method comprising administering to the subject a composition described herein. In certain embodiments, the skin condition is atopic dermatitis, psoriasis, skin aging, a condition associated with skin aging, or a pressure sore. In some embodiments, the skin condition is pruritus (itch), psoriasis, eczema, burns, or dermatitis. In certain embodiments, the skin condition is psoriasis. In certain embodiments, the skin condition is pruritus.
[0175] In certain embodiments, the compositions of the present disclosure include, in addition to amino acids, agents useful for delaying, minimizing, or eliminating skin aging, wrinkling, and / or other histological changes commonly associated with intrinsic conditions (aging, menopause, acne, etc.) and extrinsic conditions (environmental pollution, wind, heat, sunlight, radiation, low humidity, harsh surfactants, etc.).
[0176] The present invention is useful for treating and / or preventing visual and / or tactile characteristics of the skin, for example, in one embodiment, reducing the length, depth, and / or other dimensions of fine lines and / or wrinkles.
[0177] In another aspect, the disclosure provides a method of treating and / or preventing a pulmonary disease in a subject in need thereof, comprising administering to the subject a composition as described herein. In certain embodiments, the composition is administered systemically or by inhalation. In another aspect, the disclosure provides a method of achieving improved pulmonary function, improved lung healing, reduced pneumonia, reduced airway resistance, and / or improved pulmonary function in a subject in need thereof, comprising administering to the subject a composition as described herein. In certain embodiments, the pulmonary condition is lung injury, pneumonia, a condition associated with airway resistance, asthma, or a pulmonary inflammatory condition. In certain embodiments, the composition is administered systemically or by inhalation.
[0178] In one embodiment, the composition applied to the skin or other tissue may further comprise collagen and / or hyaluronic acid (HA). In one embodiment, the HA is cross-linked HA. The composition may further comprise, but is not limited to, a dermatologically acceptable carrier, desquamating agents, anti-acne agents, anti-wrinkle / anti-atrophy agents, vitamin B3 compounds, retinoids, hydroxyl acids, antioxidants / radical scavengers, chelating agents, flavonoids, anti-inflammatory agents, anti-cellulite agents, local anesthetics, sunscreens, whitening agents, skin soothing and healing agents, antibacterial and antifungal agents, sunscreens, conditioning agents, structuring agents, thickening agents (including thickening agents and gelling agents), formulations and preservatives. In this regard, International Publication WO2008 / 089408 is incorporated herein by reference in its entirety.
[0179] The compositions of the present disclosure may also be administered at surgical sites, including minimally invasive surgical sites, to improve healing and surgical outcomes.
[0180] Stem cells can also be used to treat infertility according to the present disclosure. In certain embodiments, a subject is first diagnosed with a condition in which stem cell survival, proliferation and / or growth would be beneficial to the subject. For example, once a subject is diagnosed with such a condition, a composition is administered to the subject in an amount and via a route capable of effecting stem cell survival, proliferation and / or growth. Preferably, such administration results in treatment (e.g., amelioration) of the condition.
[0181] Use of a composition for promoting proliferation and / or growth of intestinal stem and / or progenitor cells, including use of the composition for treating diseases or conditions associated with mucosal barrier function, skin conditions, lung diseases, and use of the composition for damaging mucosal barrier function and GI mucosa The present specification describes the use of amino acid compositions to treat gastrointestinal, pulmonary and skin diseases. In certain embodiments, the compositions of the present invention can be used to induce intestinal epithelial cell proliferation and increase the height of the villi. The villi contain mature and differentiated epithelial cells, which increase electrolyte and nutrient absorption. In one embodiment, the compositions according to the present disclosure stimulate the proliferation and differentiation of stem and / or progenitor cells. This is demonstrated by the increased expression levels of NHE3 and SGLT1 in the brush border membrane. Therefore, the compositions increase the height of the villi and also increase the expression of important transporters for electrolyte and nutrient absorption.
[0182] Thus, in one embodiment, the present disclosure provides pharmaceutical compositions for preventing or treating gastrointestinal damage associated with loss of small intestinal epithelial cells, particularly in the villous region and brush border, and / or for treating or ameliorating diseases or conditions associated with altered absorptive capacity of the small intestine by promoting differentiation or proliferation of stem cells. These stem cells are located in the lower part of the intestinal crypts and comprise the fast cycling crypt basal columnar cells (CBC) and the more inactive "+4" cells above the mammalian Paneth cells.
[0183] The present disclosure further provides a method for treating or ameliorating diseases or conditions associated with loss of small intestinal epithelial cells, particularly in the villous region and brush border, and diseases or conditions associated with altered transport protein function in the small intestinal epithelium, by promoting stem cell differentiation and proliferation. The method comprises administering to a subject in need of said treatment an effective amount of a composition of the present disclosure. In another aspect, the present disclosure provides a method for treating and ameliorating diseases or conditions associated with mucosal barrier function (e.g., wound healing), treating skin conditions (e.g., atopic dermatitis, psoriasis, pressure sores, or conditions associated with skin aging), treating lung diseases (e.g., asthma), improving mucosal barrier function, and / or treating damage to the GI mucosa in a subject in need thereof.
[0184] <Preparation and kit> The present disclosure provides a therapeutic or pharmaceutical composition comprising a therapeutically effective amount of the composition of the present invention and, optionally, one or more pharma- ceutically acceptable carriers. The present disclosure provides a therapeutic, pharmaceutical, cosmetic, or nutritional composition comprising a therapeutically effective amount of the composition of the present invention and, optionally, one or more pharma- ceutically acceptable carriers. The pharma- ceutically acceptable carrier may be a liquid, such as water. The therapeutic composition may also include materials that facilitate processing of the active compound into a pharma- ceutical usable preparation, such as excipients, adjuvants, flavoring agents, and the like. The appropriate formulation depends on the route of administration selected. In one embodiment, the therapeutic composition and all components contained therein are sterilized. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin. Such compositions include a therapeutically effective amount of the therapeutic composition together with a suitable amount of carrier to provide a suitable dosage form to the patient. The preparation is also suitable for administration in enteral form.
[0185] In one embodiment, administration of the composition can be systemic. Other modes of administration include oral, intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, intraventricular, intranasal, transmucosal, subcutaneous, topical, rectal, and others are all contemplated.
[0186] In one embodiment, for injection, the active ingredient can be prepared in an aqueous solution, preferably in a physiologically compatible buffer. For transmucosal administration, a penetrant suitable for permeating the barrier is used in the preparation. Such penetrants are generally known in the art. For oral administration, the active ingredient is used in combination with a suitable carrier for inclusion in tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. The preparation can also be prepared for use in inhalation therapy. For administration by inhalation, the composition can be delivered in the form of a pressurized pack or aerosol spray by a nebulizer using a suitable propellant. The composition can also be administered as a powder by inhalation or other routes.
[0187] The therapeutically effective amount of the compositions described herein can be determined by those skilled in the art to achieve a desired number of stem cells and / or progenitor cells. The increase in the number of stem and progenitor cells can be assessed using markers for these cells, or by determining the increase in the number of differentiated progeny of these cells. Methods for measuring the increase in the number of differentiated cells are known in the art. For example, immunohistochemistry, behavioral evaluation, or electrophysiological techniques can also be used. Those skilled in the art can easily detect the increase in the number of cells of a particular phenotype.
[0188] In certain embodiments, the method according to the present disclosure includes administering the therapeutic composition by a sustained release system. Suitable examples of sustained release systems include suitable polymeric materials (e.g., semipermeable polymer matrices in the form of shaped articles such as films or microcapsules), suitable hydrophobic materials (e.g., as an emulsion in an acceptable oil), or ion exchange resins, and sparingly soluble derivatives (e.g., as a sparingly soluble salt). Sustained release compositions can be administered orally, parenterally, intravesically, intraperitoneally, topically (by powders, ointments, gels, drops or transdermal patch), or as an oral or nasal spray. Examples of sustained release matrices include polylactides (U.S. Pat. No. 3,773,919; European Patent No. 58,481), copolymers of L-glutamic acid and γ-ethyl-L-glutamate [Sidman et al., Biopolymers 22:547-556, 1983, poly(2-hydroxyethyl methacrylate)); (Langer et al., J. Biomed. Mater. Res. 15:167-277, 1981; Langer, Chem. Tech. 12:98-105, 1982, ethylene vinyl acetate (Langer et al., Id.) or poly-D-(−)-3-hydroxybutyric acid (EP 133,988)].
[0189] In one embodiment, implantable drug infusion devices can be used to provide a patient with a constant long-term administration or infusion of a therapeutic composition. Such devices can be classified as active or passive.
[0190] In one embodiment, polymers can be used for ion-controlled release. A variety of degradable and non-degradable polymer matrices are known in the art for use in controlled drug delivery [Langer, Accounts Chem. Res. 26:537, 1993]. For example, block copolymers, polaxamer 407, hydroxyapatite, and liposomes.
[0191] The pharmaceutical composition of the present invention can be used alone, but can also be used in combination with one or more drugs known to be effective in treating diseases. The composition can also be prepared in combination with at least one other agent, such as a stabilizing compound or a buffering compound. The compound can be administered in a sterile biocompatible pharmaceutical carrier, such as, for example, saline, buffered saline, dextrose, and water. In addition to the cells or influencing factors, which are important components described herein, the composition can include a suitable pharmaceutically acceptable carrier, which includes excipients and auxiliary agents that facilitate the processing of the active compound into a pharmaceutically usable preparation. The composition can be prepared in a unit dose form or can be contained in a multi-dose container using a pharmaceutically acceptable carrier or excipient.
[0192] In one embodiment, the composition may further comprise other proliferation and / or differentiation inducers. The proliferation or differentiation inducers may be any agent known to induce proliferation or differentiation. Examples include fibroblast growth factor (FGF), epidermal growth factor (EGF), and retinoic acid.
[0193] The composition may further contain other commonly used additives such as antioxidants, buffers, bacteriostatic agents, etc. In addition, by further adding diluents, dispersants, surfactants, binders, lubricants, etc., the composition can be prepared into injectable preparations such as aqueous solutions, suspensions, emulsions, pills, capsules, granules, tablets, etc.
[0194] The food composition of the present invention can be included in a health functional food.
[0195] The health functional food of the present invention can be produced by a method generally adopted in the art, and raw materials and ingredients generally used in producing health functional foods can be added.
[0196] When the composition of the present invention is included in a health functional food, the composition can be added alone or together with other health functional foods or other food ingredients according to a commonly used method. The amount of active ingredient can be appropriately determined according to the purpose of use (e.g., prevention, health improvement, or therapeutic intervention). The food composition can further include, for example, a prebiotic substance or a probiotic substance.
[0197] The type of food is not limited. Examples of foods to which the composition can be added include, but are not limited to, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, soup, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.
[0198] Also encompassed in the present disclosure are kits (e.g., pharmaceutical, therapeutic, cosmetic, or nutritional packs). The kits may include a pharmaceutical composition or compound described herein and a container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispenser package or other suitable container). In some embodiments, the kits may optionally further include a second container that includes a pharmaceutical excipient for diluting or suspending the pharmaceutical composition or compound described herein. In some embodiments, the pharmaceutical composition or compound described herein is contained in a first container and a second container, and the first and second containers are combined to form a unit dosage form.
[0199] Thus, in one aspect, a kit is provided that includes a first container that includes a composition described herein. In certain embodiments, the kit is useful for treating a condition (e.g., GI, pulmonary, and skin conditions) in a subject in need of such treatment. In certain embodiments, the kit is useful for preventing a condition (e.g., GI, pulmonary, and skin conditions) in a subject in need of such prevention.
[0200] In certain embodiments, the kits described herein further comprise instructions for using the compositions contained therein. The kits described herein may also comprise information required by regulatory authorities, such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information contained in the kit is prescribing information. In certain embodiments, the kit and instructions provide for the treatment and / or prevention of a disease (e.g., GI, pulmonary, and skin disorders) in a subject in need thereof. The kits described herein may comprise one or more additional pharmaceutical agents or other formulations described herein as separate compositions.
[0201] <Method of administration> In one embodiment, the disclosure comprises administering a composition according to the disclosure to a subject and further comprising administering stem and / or progenitor cells to the subject, the composition being administered to a locus in said subject such that it is capable of contacting the cells, which may be at the same location as the stem cells are administered, or nearby, or at a location distant thereto.
[0202] The stem and / or progenitor cells can be administered, for example, by injecting one or more cells using a syringe, or by inserting the stem cells using a catheter, or by surgically implanting the stem cells. In certain embodiments, the stem cells are administered into a body cavity that is in fluid communication with the target tissue. In some preferred embodiments, the body cavity is a ventricle. In other embodiments, the cells are inserted using a syringe or catheter, or surgically implanted directly at the target tissue site. In other embodiments, the stem and / or progenitor cells are administered parenterally. Parenteral administration is defined as administration by a route that bypasses the gastrointestinal tract. Parenteral administration includes intraventricular administration.
[0203] In general, the compositions can be administered by any of a number of routes, including oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracerebroventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Factors can be administered at the same location as the administered stem cells. Administration of influencing factors and stem cells can be simultaneous or tandem, at the same location or at different locations, so long as the relative locations and timing allow the factors to affect stem and / or progenitor cells.
[0204] For example, by using "consisting essentially of," the therapeutic composition does not include any unspecified ingredients, including, but not limited to, free amino acids, di-peptides, oligo-peptides or polypeptides or proteins, and mono-, di-, oligo-, polysaccharides and carbohydrates that have a direct beneficial or detrimental therapeutic effect on promoting stem cell growth. Also, by using the term "consisting essentially of," the composition may include substances that have no therapeutic effect on promoting stem cell development, including carriers, excipients, adjuvants, flavorings, etc. that do not affect the promotion and / or growth of stem cells.
[0205] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and various modifications or changes that may be suggested to those skilled in the art should be included within the spirit and scope of the present application. EXAMPLES
[0206] Materials and Methods Animal model: 8-week-old male NIH Swiss Mouse Mice were fed a normal diet and housed with four mice per cage. Mice were irradiated using a Gammacell 40 Exactor LowDose Research Irradiator (Best Theratronics, Ottawa, Ontario) that housed two cesium-137 sources in a parallel, opposing geometry to deliver isotropic irradiation with dose uniformity within ±3%. Mice received a single dose of TBI at a dose rate of 0.9 Gy / min. Mice were fixed in the center of the irradiation chamber with a plastic jig to allow five mice to be irradiated simultaneously. Mice treated with the preparation received AA-ORS once daily by gavage (0.3 ml / mouse). The control group received normal saline. The amino acid preparation was given as supportive care and was not part of the replacement therapy. Mice were fasted for 8 h before gavage. Anion secretion peaked 6 days after irradiation, at which time animals were given CO 2 The animals were humanely euthanized by inhalation and cervical dislocation (per AVMA guidelines for euthanasia of animals). Toxicity was primarily due to acute GI syndrome, with minimal disturbance due to bone marrow syndrome. 18 After blood was removed, ileal mucosa was obtained as previously described. 18,20 All experiments were approved by the Florida Institutional Animal Care and Use Committee (IACUC) and performed under IACUC protocol #3875.
[0207] <Counting crypts and measuring villus length> Paraffin sections (5 μm) were obtained from intestinal sections cut perpendicular to the long axis of the intestine. Crypts per circumference were counted and villus length was measured from 10 sections obtained from the ileum. To determine cell survival curve parameters, crypt numbers were normalized and analyzed using classical methods. 21 AA-ORS treatment was performed for 6 days. Saline was used as a control.
[0208] <Cell proliferation and crypt-to-villus migration assay> Cell proliferation studies in the crypt cell region were performed using incorporation of 5-ethynyl-2'-deoxyuridine (EdU, a thymidine analog) into cellular DNA and subsequent reaction of EdU with fluorescent azide in copper catalysis. To assess mitotic activity in crypt cells (these studies reveal S-phase in the crypts), mice were injected with 150 ml of PBS containing 0.5 mg EdU (16.7 mg / Kg) and euthanized at 24, 48 and 72 hours post-injection. Paraffin sections were prepared from mouse ileum and incorporated EdU (Thermo Fisher Scientific Cat. No. A10044) was visualized according to the manufacturer's instructions (Alexa 647 Imaging Kit, Cat. No. C10340). Sections were then mounted in fluorescent mounting medium containing DAPI (VectaShield, Cat. No. H-1200). Cells were recorded throughout the crypt and per villus unit. More than 60 crypts and corresponding villi were analyzed per mouse. EdU-labeled cells were normalized to the total cell number per crypt or villi. Positively stained enterocytes were shown to migrate from the base of the crypt to the tip of the villi.
[0209] <Flux tests for sodium and chloride absorption> The peeled ileal sheet was cut into 0.3 cm pieces. 2 The rat was mounted between the two halves of an Ussing chamber with an exposed surface area of 100 mm (P2304, Physiological Instruments, San Diego, CA, USA). Ringer's solution was (mmol.1 -1 )Na + 140, Cl - 119.8, K + 5.2, HPO 4 - 2.4, H 2 PO 4 - 0.4, Mg 2+ 1.2, Ca 2+ 1.2, and HCO 3 - 25, and the Rinkel solution was diluted with 95% O 2 and 5% CO 2 The tissue was allowed to stabilize for 45 min, and then the μeq·h -1 ·cm -2 The base short-circuit current (I sc ) and mS.cm -2 Conductance (G), expressed as σ, was recorded using a computer-controlled voltage / current clamp apparatus (VCC MC-8, Physiological Instruments) as previously described. 18,20 For flux tests, sodium ( 22 Na) and chloride ( 36 Radioisotopes of 1,2-dichlorophenylchloride (Cl) were used to study sodium and chloride flux across the ileal mucosa as previously described. 18,2022 The Na activity was measured using a gamma counter (Wizard 2, 2480 Automatic Gamma Counter, Perkin Elmer, USA). 36 C1 was measured using a liquid scintillation counter (LS 6500 Multipurpose Scintillation Counter, Beckman Coulter, Inc., Brea, CA, USA).
[0210] <Real-time quantitative polymerase chain reaction (PCR)> RNA was extracted from intestinal tissue samples of non-irradiated and irradiated mice (0 Gy, 5 Gy, and 7 Gy) using the TRIZOL method. c-DNA was prepared using a c-DNA kit (iScript® Select cDNA Synthesis Kit, Bio-Rad, Hercules, CA). Semi-quantitative and real-time PCR were performed using specific oligonucleotide primers for caspase 3, Lgr5, sglt1, and BMI1. For semi-quantitative PCR, c-DNA (2 μL) was added to 25 μL of PCR mixture, and for quantitative PCR, 20 μL of SyBr green mixture was added. A Veriti Thermal Cycler (Thermo Fisher Scientific, Waltham, MA) was used for semi-quantitative PCR, and a CFX Connect Real-time Thirty cycles of PCR (or more than 30 cycles as indicated in the results) were performed using a PCR Cycler (Bio-Rad). One cycle consisted of 30 seconds at 94°C for denaturation, 60 seconds for annealing, and 90 seconds at 72°C for extension. Amplicons were separated by agarose gel electrophoresis and detected by ethidium bromide staining. Real-time analysis was performed using CFX Manager® software (Bio-Rad). Normalization was performed using the delta-delta Ct (DDCt) method. Briefly, DCt = Ct (target gene treatment) - Ct (ref gene treatment) and DCt = Ct (target gene control) - Ct (ref gene-control), and DCt = Ct (target gene-control) - Ct (ref gene-control). Therefore, DDCt = DCt (treatment) - Ct (control). Fold change was calculated using the formula 2 (-DDCt) Calculated from.
[0211] <Western blot> Whole cell lysates from non-irradiated mice and from irradiated AA-ORS-treated or saline-treated mice were prepared in ice-cold RIPA buffer [50 mmol / L Tris-HCl (pH 7.4), 150 mmol / L NaCl, 1% IGEP AL, 1 mmol / L EDTA, 0.25% sodium deoxycholate, 1 mmol / L sodium fluoride, 1 mmol / L sodium orthovanadate, 0.5 mmol / L PMSF, 10 μg / mL aprotinin, 10 μg / mL leupeptin]. Protein concentrations in each extract were determined by BCA assay (Sigma, St. Louis, MO). Cell extracts were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred to polyvinylidene difluoride (PVDF) membranes and probed with primary antibodies detecting Lgr5, SGL T1, Bmi 1, caspase 3, p ERK, and total ERK. Signals were detected with a LI-COR Odyssey CLX. Reversible Ponceau S staining (catalog no. 786-575, G) was performed according to the manufacturer's instructions. Equal loading of gels was examined using a chromatographic filter (Microelectronics Biosciences). The abundance of the protein of interest was normalized to the total amount of protein in each lane. This technique minimizes the variation associated with comparing protein densities to a single protein.
[0212] Immunohistochemical identification of nuclear proteins PCNA and Ki-67, and stem cell specific membrane protein Lgr5 was performed using polyclonal anti-mouse rabbit GPCR (Lgr5) (Abeam Cat. No. ab75732), Ki-67 (Abeam Cat. No. ab15580), and PCNA (Abeam Cat. No. ab18197) antibodies. Protein expression was visualized using a rabbit specific ABC detection kit (Abeam Cat. No. ab64261) according to the manufacturer's instructions. Briefly, formalin-fixed, paraffin-embedded full-thickness ileum samples were cut into 4 μm-thick cross sections, and the samples were mounted on Superfrost Plus glass slides, deparaffinized, and rehydrated. For antigen retrieval, heating pretreatment was performed using a pressure cooker (125°C for 30 s, 90°C for 10 s) and retrieval buffer. The buffer was Deloaker RTU buffer (Biocare Medical Catalog No. RV1000MMRTU) at pH 6.0. After quenching endogenous peroxidase and blocking non-specific binding, sections were incubated with primary antibodies diluted in PBS (Lgr5-1:100 for 2 hours, Ki-67-1:1000 for 15 minutes, and PCNA-1:4000 for 2 hours at room temperature). PBS was used as a negative control. Tissues were then incubated with biotinylated goat anti-rabbit secondary antibody for 10 minutes. After incubation with streptavidin peroxidase, the desired staining intensity of di-amino-benzidine was obtained by visualization under a microscope. Sections were counterstained with Mayer's hematoxylin (Electron Microscopic Sciences (EMS) Catalog No. 26043-05), dehydrated, and mounted in Permount mounting medium (Fisher Scientific Catalog No. SP15-100). Slides were evaluated by light microscopy using a 20x objective for PCNA and Ki-67 and a 40x oil-immersion objective for Lgr5. The number of positive brown cells was counted and analyzed from 50 crypts per group.
[0213] <Statistics> Results are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed in the following steps: 1) overall differences were tested using analysis of variance (ANOVA) (or its nonparametric equivalent, Kruskal-Wallis); and 2) Bonferroni-adjusted P values were calculated for all pairwise comparisons.
[0214] Example 1: AA-ORS Increased Crypt Number and Villus Length in Intestinal Tissue of Irradiated Mice Intestinal tissue from irradiated mice (5–15 Gy) treated with AA-ORS showed a significant increase in the number of crypts (N) per circumference. Because crypts are formed by regenerative units, these results indicate an increased number of progenitor epithelial cells. Similarly, AA-ORS treatments showed a significant increase in the length of the villi across all radiation doses compared to saline treatments (Figure 1B). This is consistent with increased progenitor cell proliferation and / or longer survival of epithelial cells before sloughing.
[0215] Crypt survival curves were modeled using a one-hit multitarget cell survival model to assess biological efficacy. Without limiting constant cell sensitivity, N values were 10.4±0.2 and 5.3±0.1 (P<0.001), indicating nearly twice as many precursor units per cycle as controls. When limited to a constant Do (4.8±0.1 Gy), the differences remained significant, ranging from 8.8±0.4 to 6.1±0.3 (P<0.001). The values of pseudothreshold dose (Dq), a composite index of crypt radiation tolerance, were 10.5±0.5 Gy in AA ORS-treated mice and 8.8±0.4 Gy in saline-treated mice (P<0.01).
[0216] The AA-ORS group had a "broad shoulder" in the low radiation dose area and an increased number of progenitor cells per intestinal circumference (less senescence) compared with the saline group (Figure 1A).
[0217] As expected, the distal portion followed an exponential relationship. Because 5 Gy was the minimum radiation dose at which a significant increase in both crypt number and villus height occurred, all subsequent studies were performed in mice irradiated with 0 and 5 Gy.
[0218] Increased weight gain and survival were found to be secondary to crypt number and villus height, increasing the surface area for absorption. AA-ORS treatment on day 6 post-irradiation demonstrated an increase in crypt number and villus height. Using a one-hit multitarget model of crypt survival, we found that the number of crypt progenitor cell units (N) per ileum circumference was significantly (P<0.001) increased without altering Do (4.8±0.1 Gy) (Figure 1A). Dq values were improved equivalent to the increased radiation tolerance of 1.7 Gy with AA-ORS treatment, indicating improved crypt survival. Crypt survival studies suggested an increase in progenitor cell units or stem cells per crypt. Therefore, using antibodies specific for intestinal stem cell markers and migration of daughter cells to the villi as a secondary effect of proliferation via EdU incorporation, we have demonstrated that the number of progenitor cell units per crypt increases. 14-16 , we investigated the effects of irradiation and AA-ORS on stem cell numbers.
[0219] Example 2: AA-ORS promotes migration of intestinal epithelial cells Ileum sections from irradiated mice treated with AA-ORS showed an increase in the number of crypts. Continuous renewal of villus epithelial cells is accompanied by continuous migration of cells along the crypt-villus axis. 23 As cells migrate along the villi, epithelial cells undergo further maturation and differentiation before migrating to the tip of the villi, where they are shed by anoikis. Cell proliferation was studied using EdU incorporation.
[0220] Cells were found to migrate from the crypt base to the villus tip after approximately 72 hours. Ileum sections from non-irradiated mice showed a mean of 76.5 hours, but the time at which cells (cells that incorporated EdU) reached the villus tip varied (75 ± 0.9 hours; n = 10). Six days of AA-ORS treatment did not show a significant difference in the length contained by the migrated cells between 0 and 5 Gy-irradiated mice (153.5 ± 6 mm vs. 158.1 ± 7 mm; n = 10 mice). However, six days of AA-ORS treatment did show a significant difference in the length contained by the 5 Gy-irradiated mice (158.1 ± 7 mm vs. 183.1 ± 4 mm; P < 0.01, n = 10 mice) (Figures 2A and 2B). These studies indicate that AA-ORS increases cell proliferation and is involved in the length contained.
[0221] Example 3 - AA-ORS Increases Sodium and Chloride Absorption AA-ORS increased villus height and proliferation in crypt cells reg10n.To determine whether functional maturation and differentiation of villous epithelial cells was due to the increased villus height, isotope flux studies were performed to determine sodium and chloride absorption.
[0222] Non-irradiated mice had a low net sodium absorption (J Net Na) was 1.9±0.6ueq.cm 2 .h- 1 and the net chloride absorption (J Net Cl) is 1.9±0.4ueq.cm 2 .h- 1 The ileum of mice irradiated with 5 Gy was J Net Na(1.9±0.6ueq.cm 2 .h- 1 0.1±0.0ueq.cm 2 .h- 1 ;p<0.001, n=8) and J Net Cl(1.9+0.4ueq.cm 2 .h- 1 -0.9±0.4ueq.cm 2 .h- 1 ) and decreased. The net sodium absorption in the ileum of 0Gy mice was 3.9±0.7ueq.cm2. 2 .h- 1 ;p<0.05, n=8) and the ileum of 5Gy mice (3.4±0.7ueq.cm 2 .h- 1 ; p < 0.001, n = 8) (Figure 3A). Similarly, AA-ORS treatment significantly increased the net chloride absorption in the ileum of 0 Gy mice (4.1 ± 0.6 ueq.cm). 2 .h- 1 p < 0.05, n = 8) and the ileum of 5 Gy mice (3.6 ± 0.6 ueq.cm 2 .h- 1 ; p < 0.001, n = 8) (Figure 3B).
[0223] These studies demonstrated increased electrolyte absorption capacity and sodium-bound glucose absorption, suggesting that the increase in villus height induced by AA-ORS is a function of the maturation and differentiation of villous epithelial cells.
[0224] Immunohistochemistry for NHE3 protein recognized NHE3 antibody along the brush border region of villous epithelial cells (Figure 3C). Little or no expression was observed along the brush border membrane in villous cells from 5 Gy-irradiated animals. AA-ORS treatment increased NHE protein expression along the border region in both 0 Gy and 5 Gy-irradiated epithelial cells (Figure 3C). Western blot analysis showed increased NHE3 protein expression in intestinal tissues in 0 Gy (3.5-fold) and 5 Gy (15.5-fold) irradiated AA-ORS-treated mice compared to irradiated, saline-treated mice (Figures 3D-E). These studies suggest that NHE3 protein is increased in the brush border membrane of villous epithelial cells. To determine whether the increase in NHE3 protein was due to an increase in NHE3 mRNA, its levels in intestinal tissues were determined using qPCR (Figure 3F). Unlike NHE3 protein levels, NHE3 mRNA levels were only significantly different in 5 Gy compared to saline-treated 5 Gy-irradiated mice. Protein levels were not well correlated with changes in NHE3 mRNA levels, and similar observations have been reported previously.
[0225] Example 4: Increase in glucose-stimulated sodium absorption by AA-ORS Glucose stimulates sodium absorption via a specific transporter located in the apical membrane of mature and differentiated epithelial cells in the villi. To determine whether the enhanced glucose absorption was due to the increased villus height induced by AA-ORS, 22 Na flux studies were used to assess glucose-stimulated sodium absorption.
[0226] Ileal tissue from 5 Gy-irradiated mice showed a significant decrease in glucose-stimulated sodium absorption (4.8±0.5ueq.cm 2 .h- 1 0.3±0.1ueq.cm 2 .h- 1 ;p<0.001, n=6). Ileal tissue from 5Gy-irradiated mice treated with AA-ORS showed a significant increase in glucose-stimulated sodium absorption (0.3±0.1ueq.cm). 2 .h- 1 3.1±0.3ueq.cm 2 .h- 1 ;p<0.001, n=6), whereas 0Gy-irradiated mice did not show this increase (4.8±0.5ueq.cm 2 .h- 1 5.9±0.7ueq.cm 2 .h- 1 ; p = ns, n = 6) (Figure 4A). AA-ORS-treated mice showed increased SGLT1 expression at the transcriptional and translational levels in 0- and 5-Gy irradiated mice compared with saline-treated mice (Figure 4B-D). These studies demonstrated that SGLT1 expression at the transcriptional and translational levels in 0- and 5-Gy irradiated mice was increased in the interdigestive phase (NHE3-mediated Na+ / Na ... + Absorption) and digestive phase (glucose-stimulated Na + These results suggest that the increase in villus height induced by AA-ORS is a function of the maturation and differentiation of villous epithelial cells, by showing that the electrolyte absorption capacity increases during AA-ORS (absorption).
[0227] Beta-galactosidase (lactose protein) levels in isolated trophoblast cells were measured using Western blot analysis. Beta-galactosidase expression occurs primarily in mature and differentiated trophoblast epithelial cells. AA-ORS treatment increased beta-galactosidase protein levels in trophoblast cells from 0 Gy and 5 Gy irradiated mice (Figure 4B).
[0228] Example 5 - Effects of AA-ORS on intestinal stem cells and proliferation markers At least three distinct crypt cell types are set out to represent intestinal stem cells (ISCs) 14 Because each member of the population has a distinct proliferation dynamic and sensitivity to radiation, each member is thought to perform a unique function. 28 They are thought to dynamically switch from one type to another in response to inhibitory and stimulatory signals elicited by cytokines, hormones, or growth factors. 28 In contrast, slowly dividing intestinal epithelial stem cells (IESCs) [label-retaining cells (LRCs)] in the +4 crypt position contribute to homeostatic regenerative capacity, especially during recovery from injury. 30 These LRCs express various markers, such as Bmil, HopX, Lrigl, and / or Dclk1, and can transform into rapidly dividing IESCs in response to injury. 31 Although Bmi1 and HopX have been reported to preferentially mark +4 cells, Lgr5 can mark both types of cells. + ISC is required 35 Lgr5 - BMI1 and BMI2 are thought to be reserve cells that initiate regenerative responses after injury or radiation-induced damage. Studies have shown that activation of the BMI1-expressing stem cell pool results in the induction of Lgr5 + This indicates that cell loss is acceptable. 14,32 .
[0229] To determine whether the increase in villus height observed with AA-ORS was due to increased stem cell number and proliferation, the effect of AA-ORS on markers of stem cells and proliferation was examined.
[0230] Irradiation significantly decreased Lgr5 protein levels (Figure 5A). AA-ORS treatment increased Lgr5 protein levels in 0- and 5-Gy irradiated mice compared with saline-treated control groups. However, intestinal tissues from 5-Gy irradiated mice showed no significant change in BMI1 protein levels compared with 0-Gy mice. Similarly, AA-ORS did not alter BMI1 protein levels in 0- and 5-Gy irradiated mice (Figure 5A). Lgr5 transcript levels, but not BMI1 levels, were significantly increased in AA-ORS-treated 0- and 5-Gy mice (Figure 5C-D).
[0231] We found that 5 Gy caused a significant decrease in Lgr5 transcript and protein levels compared to 0 Gy, without significant changes in Bmil levels. AA-ORS treatment significantly increased Lgr5 mRNA and protein levels without significant changes in Bmil, suggesting an increase in Lgr5-positive stem cells. These results also show that intestinal sections from irradiated mice treated with AA-ORS were significantly longer covered by migrating cells than saline-treated mice. Since transcription is halted in cells undergoing apoptosis, increased cell viability would preferentially increase short-lived transcripts such as Lgr5 over long-lived transcripts. BMI1 protein levels in intestinal tissue did not change in response to radiation or AA-ORS, suggesting that the reserve population of ISCs is not affected at the radiation doses studied. Furthermore, the increase in Lgr5 protein levels by AA-ORS supports the observation in crypt number studies that AA-ORS treatment after increasing radiation doses leads to increased ISC numbers when fitted as a one-hit multitarget model.
[0232] Western blot analysis of ERK1 / 2 and pERK1 / 2 was performed using total cell fractions to evaluate the effects of radiation and AA-ORS on proliferation. To determine the transcriptional levels of ERK and AKT, qPCR studies were performed in epithelial cells isolated from 0 Gy and 5 Gy irradiated tissues, both with and without treatment. ERK1 / 2 and AKT are phosphorylated upon activation. Western blot analysis showed that p-ERK protein levels were significantly different between 0 Gy and 5 Gy (Figure 5A). Total ERK protein levels were not significantly different between AA-ORS and saline-treated mice at 0 or 5 Gy. Similarly, for ERK, AA-ORS-treated 0 and 5 Gy mice showed no significant difference in AKT levels, but p-AKT protein levels were elevated compared to the corresponding saline-treated irradiated groups. Intestinal tissue from 5 Gy mice showed a significant decrease in p-AKT compared to 0 Gy mice.
[0233] These studies suggest that AA-ORS treatment increases the phosphorylation levels of proteins without altering the expression of total proteins. Because the effect of MAPK depends on downstream effectors of activating transcription factor 4 (Atf4), the protein levels of Atf4 were measured using Western blot analysis. 5 Gy irradiation reduced the protein levels of Atf4, whereas AA-ORS treatment increased the protein levels of Atf4 in 0 Gy and 5 Gy-irradiated mice. Examination of ERK and AKT transcript levels using qPCR showed that 5 Gy irradiation resulted in a significant decrease in mRNA levels compared to 0 Gy. AA-ORS treatment showed a significant increase at 0 Gy and 5 Gy compared to saline-treated mice (Figure 5E-F). Early changes in normal cell proliferation in the intestinal tract serve as an indicator of deviation from normal gastrointestinal function. Changes in the expression of the proliferating cell nuclear antigen (PCNA), a 36 kD protein, are recognized as one of the markers of changes in the gastrointestinal tract. AA-ORS increased PCNA protein levels in 0 Gy and 5 Gy irradiated mice (FIG. 5A).
[0234] We also investigated the effect of AA-ORS on B-cell lymphoma-2 protein (Bc1-2), a downstream target of Erk1 / 2. Bcl-2 prevents cell death rather than promoting cell proliferation by regulating the expression levels of the proapoptotic Bcl-2-associated X protein (Bax) in the endogenous caspase cascade. In 0 Gy mice, Bc1-2 levels were elevated by AA-ORS treatment. Irradiation led to a significant increase in Bcl-2 protein levels. Treatment with AA-ORS did not show a further increase in Bc12 protein levels in mice irradiated with 5 Gy (Figure 5B). The increase in Bcl-2 protein levels by irradiation may suggest a defense mechanism to prevent apoptosis. However, Western blot analysis using a Bax-specific antibody showed no significant differences in protein levels (Figure 5B). This study is consistent with previous observations that interventions targeting Bc1-2 do not necessarily alter the protein levels of Bax4.
[0235] AA-ORS increased p-ERK. This study suggests that amino acids act to maintain mitogenic stimulation from late G1 to S phase. 38 .
[0236] In this study, we showed that radiation increased caspase-3 and AA-ORS treatment decreased cleaved caspase-3 in trophoblastic epithelial cells from 0 and 5 Gy mice. The increase in pAKT in AA-ORS-treated mice suggests that the effect may be due to activation of proliferation or inhibition of apoptosis (Figure 5). Together with the effect seen on caspase-3, these results could explain the pro-survival effect and increased proliferation observed with AA-ORS treatment. However, further studies are essential to characterize the mechanism by which AA-ORS activates ERK1 / 2 and AKT or caspase-3.
[0237] Example 6: Reduction of cleaved caspase-3 and caspase-3 transcript levels by AA-ORS Activation of caspase-3 generates a 19 kD cleaved form of caspase-3. Cleaved caspase-3 increases with apoptosis. Western blot analysis showed no significant difference in total caspase-3 after irradiation and treatment compared to controls. Intestinal tissue from 5 Gy mice showed a significant increase in cleaved caspase-3 compared to tissue from 0 Gy mice. However, cleaved caspase-3 was decreased in AA-ORS when compared to the corresponding irradiated controls (Figure 5B). Caspase-3 mRNA levels measured using qPCR showed a significant increase in caspase-3 transcript levels after 5 Gy irradiation compared to 0 Gy. Treatment with AA-ORS resulted in a significant decrease in caspase-3 transcript levels in intestinal tissue from 0 Gy and 5 Gy irradiated mice (Figure 5G).
[0238] The increase in villus height in intestinal tissue of non-irradiated and irradiated mice by AA-ORS was due to a decrease and increase in apoptosis as well as proliferation, as suggested by the changes in cleaved caspase-3, along with Lgr5, p-ERK, and p-AKT.
[0239] To assess whether villous epithelial cells are mature, differentiated, and functionally active resulting from increased proliferation and / or decreased apoptosis, we measured sodium absorption capacity and glucose-stimulated sodium absorption. Both NHE3, the major transporter for sodium absorption in the small intestine, and SGLT1, the transporter for sodium-bound sodium absorption, occurred only in mature and differentiated villous cells and showed increased function (Figures 3A-F and 4A-D), as well as elevated mRNA and protein levels. These studies suggest that treatment with AA-ORS after radiation increases electrolyte and glucose absorption (Figures 5A-G).
[0240] Example 7: Western blot analysis of total p53 p53 is a tumor suppressor protein whose activity prevents tumor formation. Mutations in the p53 tumor suppressor gene are the most frequently observed genetic lesions in human cancers. Mice homozygous for the null allele appear normal but are prone to spontaneously developing a variety of tumors. p53 has been shown to have an important role in the response to irradiation. The level of p53 accumulation in response to irradiation results primarily from the intensity of DNA damage. It has been demonstrated that stem cell loss plays an important role in radiation-induced acute intestinal injury and lethality and is regulated by the p53 pathway and its transcriptional targets PUMA and p21. PUMA-dependent apoptosis rapidly reduces ISCs and their progenitors within hours of high-dose irradiation, and PUMA deficiency is crucial for radiation-induced intestinal injury as it enhances animal survival and crypt regeneration by enhancing p21-dependent DNA repair.
[0241] Western blot analysis showed no significant difference in p53 (a tumor suppressor protein) levels in intestinal tissues of 0 and 5 Gy mice. The increase in p53 protein levels by AA-ORS was small but consistent (Figure 5B).
[0242] These studies suggest that the proliferative effects associated with AA-ORS are not involved in tumorigenesis.
[0243] Example 8: Immunohistochemistry Lgr5 + The avidin-biotin detection method using a polyclonal antibody against intestinal stem cells showed that radiation-induced Lgr5 + Treatment with AA-ORS showed a significant decrease in Lgr5 cells in 0 Gy-irradiated mice (3.0 ± 0.2 vs. 1.6 ± 0.2; P < 0.001, n = 50 crypts). + However, in 5 Gy-irradiated mice, AA-ORS treatment significantly increased Lgr5 expression. + The number of cells increased (1.6 ± 0.2 vs. 3.4 ± 0.3; P < 0.001, n = 50 crypts) (Figures 6A-B).
[0244] Ki-67 is a nuclear protein that is a cellular marker for proliferation and is associated with ribosomal RNA transcription. Ki-67 also regulates all active phases of the cell cycle (G 1 , S., G. 2 and mitosis), but not in resting cells (G 0 ) was absent in the ileal sections. Ileal sections showed Ki67 expression along parts of the crypts except the lower pole, with expression extending to the lower third of the villi. Radiation did not result in significant differences in Ki-67 expression, but treatment with AA-ORS significantly increased Ki-67-expressing cells (50.7 ± 1.3 vs. 54.6 ± 1.4; P < 0.05, n = 50 crypts) (Figures 6C-D).
[0245] Immunostaining for PCNA in ileal sections showed expression along the crypts except at the lower pole. Irradiation significantly decreased PCNA expression in both the crypts and the lower regions of the villi (31.1 ± 0.8 vs. 26.6 ± 0.6; P < 0.001, n = 50 crypts). Treatment with AA-ORS showed a significant increase in PCNA expression in 5 Gy mice (26.6 ± 0.6 vs. 34.2 ± 0.5; P < 0.001, n = 50 crypts), but not in 0 Gy mice (Figure 6E-F).
[0246] Western blot analysis showed that cell homogenates from small intestinal mice irradiated at 5 Gy showed a significant increase compared to 0 Gy. Mice treated with AA-ORS had elevated Ki67 protein levels at 0 Gy, but no further increase was observed at 5 Gy. These studies suggest that AA-ORS-induced epithelial proliferation is mediated by Ki67 at 0 Gy but not at 5 Gy.
[0247] This study shows that systematic selection of specific nutrients based on their beneficial effects on gut function is useful to improve intestinal stem cell proliferation, maturation and differentiation, and that the function and height of functionally active long villus epithelial cells are initially impaired by irradiation (Figure 7).
[0248] Example 9: Improvement of gastrointestinal function in mice by AA-ORS Using electrophysiological techniques, it has been shown that radiation-induced Cl secretion can occur at radiation doses too low to produce obvious histopathological changes. 55 Radiation-induced intestinal dysfunction is associated with (1) increased Cl secretion and increased fluid secretion; (2) increased Na + and (3) increased paracellular permeability, resulting in increased transfer of intraluminal antigenic material to the systemic compartment, resulting in local and systemic immune responses. Increased penetration of intraluminal material into the systemic compartment results in increased plasma endotoxins and inflammatory cytokines (e.g., IL1β). 51 .
[0249] As outlined in a previous study, an amino acid-based oral rehydration solution (AA-ORS) was previously developed. 51 The specific amino acids selected were determined based on the results of the study, which showed that the selected amino acids were: (1) Na + By binding with Na + (2) Increased the absorption of Cl - (3) did not stimulate secretion, i.e., fluid secretion; and (4) reduced paracellular permeability or mucosal barrier tightness. AA-ORS treatment for 14 days improved electrolyte absorption, reduced paracellular permeability, reduced plasma endotoxin and proinflammatory cytokine levels, maintained body weight better, and was shown to be more effective than another lethal dose of total body irradiation (8.5 Gy TBI). 51 AA-ORS improved survival in mice exposed to it. Subsequent studies showed that these improvements occurred as early as 7 days after treatment, although the exact mechanisms of these effects are unknown.
[0250] In summary, AA-ORS containing a selected set of amino acids are identified as intestinal radiation mitigating agents in mice by selectively enhancing stem cell markers such as Lgr5 and BMI1, and by blocking caspase-3-mediated apoptosis in intestinal stem and progenitor cells. Therefore, this study implies the effect of simple amino acids on the proliferation, maturation and differentiation of intestinal stem cells, and the function and height of functionally active long villous epithelial cells are initially impaired by irradiation.
[0251] The examples and embodiments described in this specification are for illustrative purposes only, and various modifications or alterations may be suggested to those skilled in the art. these are within the spirit and scope of this application. Also, any element or limitation of any invention or embodiment disclosed in this specification may be combined (individually or arbitrarily) with any and / or all other elements or limitations described in this specification, or with other inventions or embodiments, and all such combinations are intended to be within the scope of the present invention, without limitation thereto.
[0252] <References> 1. Adams, PD et al. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 16, 6623-6633 (1996). 2. Barker, N., van Oudenaarden, A. & Clevers, H. Identifying the stem cell of the intestinal crypt: strategies and pitfalls. Cell Stem Cell 11, 452-460, doi:10.1016 / j.stem.2012.09.009 (2012). 3. Bullwinkel J, Baron-Luhr B, Ludemann A, et al. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006;206:624-35. 4. Cheng, H. & Leblond, C. P. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. Am J Anat 141, 537-561 (1974). 5. Citrin, D. et al. Radioprotectors and mitigators of radiation-induced normal tissue injury. 6. Crosnier, C., Stamataki, D. & Lewis, J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 7, 349-359, doi:10.1038 / nrg1840 (2006). 7. Cryns, V. & Yuan, J. Proteases to die for. Genes Dev 12, 1551-1570 (1998).8. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004). 9. Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev 13, 2905-2927 (1999). 10. Davis, N. M. et al. Deregulation of the EGFR / PBK / PTEN / Akt / mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5, 4603-4650, doi: 10.18632 / oncotarget.2209 (2014).
[0253] 11. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221, doi:10.1038 / 356215a0 (1992). 12. Fei, P. & El-Deiry, W. S. P53 and radiation responses. Oncogene 22, 5774-5783, doi: 10.1038 / sj.onc.1206677 (2003). 13. Fukuda, M., Gotoh, Y. & Nishida, E. Interaction of MAP kinase with MAP kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBOJ16, 1901-1908, doi:10.1093 / emboj / 16.8.1901 (1997). 14. Gopal, R. et al. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oneal Biol Phys 56, 106-113 (2003). 15. Greenberger, J. S. Radioprotection. In Vivo 23, 323-336 (2009). 16. Hahn, S. M. et al. Identification of nitroxide radioprotectors. Radiat Res 132, 87-93 (1992). 17. Hall, P. A. & Lane, D. P. Tumor suppressors: a developing role for p53? Curr Biol 7, R1 44-14 7 (1997). 18. Hauer-Jensen, M., Wang, J. & Denham, J. W. Bowel injury: current and evolving management strategies. Semin Radiat Oncol 13, 357-371 (2003). Health Phys 106, 734-744, doi:10.1097 / HP.0000000000000117 (2014). 19. Houghton, J. et al. Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571, doi:10.1 126 / science.1099513 (2004). 20. Kahan, C., Seuwen, K., Meloche, S. & Pouyssegur, J. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. J Biol Chem 267, 13369-13375 (1992). 21. Kandel, E. S. et al. Activation of Akt / protein kinase B overcomes a 0(2) / m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22, 7831-7841 (2002). 22. Karam, S. M. Lineage commitment and maturation of epithelial cells in the gut. Front Biosci 4, D286-298 (1999). 23. Komarova, E. A. et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23, 3265-3271, doi: 10.1038 / sj.onc.1207494 (2004). 24. Leibowitz, B. J. et al. Uncoupling p53 functions in radiation-induced intestinal damage via PUMA and p21. Mol Cancer Res 9, 616-625, doi:10.1158 / 1541-7786.MCR-11-0052 (2011).
[0254] 25. Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010;327:542-5. 26. Li, X. M., Hu, Z., Jorgenson, M. L., Wingard, J. R. & Slayton, W. B. Bone marrow sinusoidal endothelial cells undergo nonapoptotic cell death and are replaced by proliferating sinusoidal cells in situ to maintain the vascular niche following lethal irradiation. Exp Hematol 36, 1143-1156, doi:10.1016 / j.exphem.2008.06.009 (2008). 27. Lu, Z. & Xu, S. ERK1 / 2 MAP kinases in cell survival and apoptosis. IUBMB Life 58, 621-631, doi: 10.1080 / 15216540600957438 (2006). 28. Marks, L. B. Dosimetric predictors of radiation-induced lung injury. Int J Radiat Oneal Biol Phys 54, 313-316 (2002). 29. Meloche, S. Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G 1 phase and their inactivation at the Gl / S transition.JCell Physiol 163, 577-588, doi:10.1002 / jcp.1041630319 (1995). 30. Metcalfe, C., Kljavin, N. M., Ybarra, R. & de Sauvage, F. J. Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14, 149-159, doi:10.1016 / j.stem.2013.11.008 (2014). 31. Nair, C. K., Parida, D. K. & Nomura, T. Radioprotectors in radiotherapy. J Radiat Res 42, 21-37 (2001). 32. Niu, Y. et al. Intraesophageal MnSOD-plasmid liposome enhances engraftment and selfrenewal of bone marrow derived progenitors of esophageal squamous epithelium. Gene Ther 15, 347-356, doi: 10.1038 / sj.gt.3303089 (2008). Oncologist 15, 360-371, doi: 10.1634 / theoncologist.2009-S 104(2010). 33. Pageot, L. P. et al. Human cell models to study small intestinal functions: recapitulation of the crypt-villus axis. Microsc Res Tech 49, 394-406, doi:10.1002 / (SICI)1097-0029(20000515)49:4<394: :AID-JEMT8> 3.0.00;2-K (2000). 34. Potten, C. S. A comprehensive study of the radiobiological response of the murine (BDF1) small intestine. Int J Radiat Biol 58, 925-973, doi:7AQN1HHQNKSERATM [pii] (1990). 35. Potten, C. S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat Res 161, 123-136 (2004). 36. Potten, C. S., Booth, C. & Pritchard, D. M. The intestinal epithelial stem cell: the mucosal governor. Int J Exp Pathol 78, 219-243 (1997).
[0255] 37. Pritchard, D. M., Potten, C. S., Korsmeyer, S. J., Roberts, S. & Hickman, J. A. amageinduced apoptosis in intestinal epithelia from bc1-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene 18, 7287-7293, doi: 10.1038 / sj.onc.1203150 (1999). 38. Qiu, W. et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2, 576-583, doi:10.1016 / j.stem.2008.03.009 (2008). 39. Ramaswamy, S. et al. Regulation of G 1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase / Akt pathway. Proc Natl Acad Sci USA 96, 2110-2115 (1999). 40. Reszka, A. A., Seger, R., Diltz, C. D., Krebs, E. G. & Fischer, E. H. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci US A 92, 8881-8885 (1995). 41. Rubin, P. & Casarett, G. W. Clinical radiation pathology as applied to curative radiotherapy. Cancer 22, 767-778 (1968). 42. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt / PKB by the rictor-mTOR complex. Science 307, 1098-1101, doi:10.1126 / science.1106148 (2005). Science 327, 542-545, doi:10.1126 / science.1180794 (2010).
[0256] 43. Shivdasani, R. A. Radiation redux: reserve intestinal stem cells miss the call to duty. Cell Stem Cell 14, 135-136, doi:10.1016 / j.stem.2014.01.015 (2014). 44. Stephens, L. et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279, 710-714 (1998). 45. Takeda, N. et al. Interconversion between intestinal stem cell populations m distinct niches. Science 334, 1420-1424, doi:10.1126 / science.1213214 (2011).46. Thornberry, N. A. & Lazebnik, Y. Caspases: enemies within. Science 281, 1312-1316 (1998). 47. Tucker, S. L., Withers, H. R., Mason, K. A. & Thames, H. D., Jr. A dose-surviving fraction curve for mouse colonic mucosa. Eur J Cancer Clin Oncol 19, 433-437 (1983). 48. Vidyasagar, S., Barmeyer, C., Geibel, J., Binder, H. J. & Rajendran, V. M. Role of shortchain fatty acids in colonic HCO3- secretion. Am J Physiol Gastrointest Liver Physiol 288, G 1217-1226 (2005). 49. Yamamoto, T. et al. Continuous ERK activation downregulates antiproliferative genes throughout G 1 phase to allow cell-cycle progression. Curr Biol 16, 1171-1182, doi: 10.1016 / j.cub.2006.04.044 (2006). 50. Yan, K. S. et al. The intestinal stem cell markers Bmi 1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci U S A 109, 466-471, doi: 10.1073 / pnas.1118857109(2012). 51. Yin L, Vijaygopal P, Menon R, et al. An amino acid mixture mitigates radiation-induced gastrointestinal toxicity. Health Phys 2014; 106:734-44. 52. Yin, L. et al. Glucose stimulates calcium-activated chloride secretion in small intestinal cells. Am J Physiol Cell Physiol 306, C687-696, doi:10.1152 / ajpce11.00174.2013 (2014). 53. Yu, J. Intestinal stem cell injury and protection during cancer therapy. Transl Cancer Res 2, 384-396 (2013). 54. Zhang, H., Ameen, N., Melvin, J. E. & Vidyasagar, S. Acute inflammation alters bicarbonate transport m mouse ileum. J Physiol 581, 1221-1233, doi:10.1113 / jphysio1.2007.129262(2007). 55. Zhang, K. et al. Radiation decreases murine small intestinal HCO3- secretion. Int J Radiat Biol 87, 878-888, doi: 10.3109 / 09553002.2011.583314 (2011).
Claims
1. A formulation for treating a pulmonary condition associated with delayed airway response and / or airway hyperresponsiveness in a subject in need of such treatment, comprising: The formulation comprises a therapeutically effective combination of free amino acids, said therapeutically effective combination of free amino acids consisting essentially of therapeutically effective amounts of the free amino acids consisting of threonine, valine, tyrosine, serine, and aspartic acid; The formulation is prepared for oral administration, The therapeutically effective combination of free amino acids is sufficient to improve the pulmonary condition associated with late airway response and / or airway hyperresponsiveness in the subject.
2. A formulation for treating a pulmonary condition associated with delayed airway response and / or airway hyperresponsiveness in a subject in need of such treatment, comprising: The formulation comprises a therapeutically effective combination of free amino acids, said therapeutically effective combination of free amino acids consisting essentially of therapeutically effective amounts of the free amino acids consisting of threonine, valine, tyrosine, serine, and tryptophan; The formulation is prepared for use in inhalation therapy, The therapeutically effective combination of free amino acids is sufficient to improve the pulmonary condition associated with late airway response and / or airway hyperresponsiveness in the subject.
3. (i) the therapeutically effective amount of threonine is at a concentration of 0.4 to 1.5 grams / liter or 0.7 to 1.3 grams / liter; or (ii) the therapeutically effective amount of valine is at a concentration of 0.7 to 1.7 grams / liter or 0.9 to 1.5 grams / liter; or (iii) the therapeutically effective amount of tyrosine is at a concentration of 0.05 to 0.4 grams per liter; or (iv) the therapeutically effective amount of serine is at a concentration of 0.6 to 1.6 grams / liter or 0.8 to 1.4 grams / liter; or (v) when aspartic acid is present, the therapeutically effective amount of aspartic acid is at a concentration of 0.4 to 3.6 grams per liter; or (vi) when tryptophan is present, the therapeutically effective amount of tryptophan is at a concentration of 1.1 to 2.1 grams / liter or 1.3 to 1.9 grams / liter; or The formulation according to claim 1 or 2, which is any combination of (i) to (vi).
4. (i) the therapeutically effective amount of threonine is at a concentration of 0.9 to 1.1 grams / liter; or (ii) the therapeutically effective amount of valine is at a concentration of 1.1 to 1.3 grams per liter; or (iii) the therapeutically effective amount of tyrosine is at a concentration of 0.1 to 0.3 grams per liter; or (iv) the therapeutically effective amount of serine is at a concentration of 1.0 to 1.2 grams per liter; or (v) when aspartic acid is present, the therapeutically effective amount of aspartic acid is at a concentration of 0.4 to 3.6 grams per liter; or (vi) when tryptophan is present, the therapeutically effective amount of tryptophan is at a concentration of 1.5 to 1.7 grams per liter; or The formulation according to any one of claims 1 to 3, which is any combination of (i) to (vi).
5. (i) the therapeutically effective amount of threonine is about 1.0 grams / liter; or (ii) the therapeutically effective amount of valine is about 1.2 grams / liter; or (iii) the therapeutically effective amount of tyrosine is about 0.2 grams per liter; or (iv) when tryptophan is present, the therapeutically effective amount of tryptophan is 1.6 grams / liter; or The formulation according to any one of claims 1 to 4, which is any combination of (i) to (iv).
6. The therapeutically effective amount of threonine is 8 mM; The therapeutically effective amount of valine is 10 mM; A therapeutically effective amount of tyrosine is 1.2 mM; When tryptophan is present, the therapeutically effective amount of tryptophan is 8 mM; When aspartic acid is present, the therapeutically effective amount of aspartic acid is 8 mM; 6. The formulation of claim 1, wherein the therapeutically effective amount of serine is 10 mM.
7. 7. A formulation according to claim 1, wherein at least one of the free amino acids is an L-type free amino acid or each of the free amino acids is an L-type free amino acid.
8. 8. The formulation of claim 1, further comprising a pharma- ceutically acceptable carrier, buffer, adjuvant or excipient.
9. 9. The formulation of claim 1, further comprising water.
10. 10. The formulation of any one of claims 1 to 9, wherein the formulation is sterile.
11. 11. The formulation of any one of claims 1 to 10, wherein the formulation is a pharmaceutical composition.
12. 12. The formulation of any of claims 2 to 11, wherein the formulation is prepared for pulmonary or intranasal administration.
13. 13. The formulation of any one of claims 1 to 12, wherein the subject is a mammal.
14. 14. The formulation of any one of claims 1 to 13, wherein the mammal is a human, cat, dog, pig, horse, sheep, or goat.
Citation Information
Patent Citations
Substances and methods for improving lung function and for the prevention and / or treatment of radiation-induced lung complications
JP2016512522A
Amino acid compositions for the treatment of symptoms of disease
WO2016085735A1
